<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VIMOVO- naproxen and esomeprazole magnesium tablet, delayed release </strong><br>Horizon Pharma Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use VIMOVO safely and effectively. See full prescribing information for VIMOVO.<br><br>VIMOVO<span class="Sup">®</span><br>(naproxen and esomeprazole magnesium) delayed release tablets, for oral use<br>Initial U.S. Approval:  2010</div>
<div class="Warning">
<div>
<h1 class="Warning"><span class="Bold">WARNING: CARDIOVASCULAR AND GASTROINTESTINAL RISKS</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning</span></h1>
<p class="Highlighta"><span class="Bold">Cardiovascular Risk</span> </p>
<ul class="Disc">
<li><span class="Bold">Naproxen, a component of VIMOVO, may cause an increased risk of serious cardiovascular thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. <span class="Italics">(<a href="#S5.1">5.1</a>)</span></span></li>
<li><span class="Bold">VIMOVO is contraindicated for the treatment of peri-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery. <span class="Italics">(<a href="#S4">4</a>, <a href="#S5.1">5.1</a>)</span></span></li>
</ul>
<p class="Highlighta"><span class="Bold">Gastrointestinal Risk</span> </p>
<ul class="Disc"><li><span class="Bold">NSAIDs, including naproxen, a component of VIMOVO, cause an increased risk of serious gastrointestinal adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal (GI) events. <span class="Italics">(<a href="#S5.4">5.4</a>)</span></span></li></ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table class="Noautorules" width="95%">
<col align="left" valign="top" width="85%">
<col align="right" valign="top" width="15%">
<tbody class="Headless">
<tr>
<td align="left">Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="4102631" conceptname="Acute interstitial nephritis">Acute Interstitial Nephritis</span> (<a href="#S5.16">5.16</a>)</td>
<td align="right">12/2014</td>
</tr>
<tr>
<td align="left" valign="bottom">Warnings and Precautions, Cyanocobalamin (vitamin B-12) Deficiency (<a href="#S5.17">5.17</a>)</td>
<td align="right" valign="bottom">12/2014</td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="Warning">
<div>
<h1 class="Warning"><span class="Bold">WARNING: CARDIOVASCULAR AND GASTROINTESTINAL RISKS</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning</span></h1>
<p class="Highlighta"><span class="Bold">Cardiovascular Risk</span> </p>
<ul class="Disc">
<li><span class="Bold">Naproxen, a component of VIMOVO, may cause an increased risk of serious cardiovascular thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. <span class="Italics">(<a href="#S5.1">5.1</a>)</span></span></li>
<li><span class="Bold">VIMOVO is contraindicated for the treatment of peri-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery. <span class="Italics">(<a href="#S4">4</a>, <a href="#S5.1">5.1</a>)</span></span></li>
</ul>
<p class="Highlighta"><span class="Bold">Gastrointestinal Risk</span> </p>
<ul class="Disc"><li><span class="Bold">NSAIDs, including naproxen, a component of VIMOVO, cause an increased risk of serious gastrointestinal adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal (GI) events. <span class="Italics">(<a href="#S5.4">5.4</a>)</span></span></li></ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Relief of signs and symptoms of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>, <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, and <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">ankylosing spondylitis</span> and to decrease the risk of developing <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span> in patients at risk of developing NSAID associated <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span> (<a href="#S1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">One tablet twice daily. Use the lowest effective dose. Should be avoided in moderate/severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> or in severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>. Consider dose reduction in mild/moderate <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> (<a href="#S2">2</a>) </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Delayed release tablets: 375 mg/20 mg or 500 mg/20 mg of naproxen and esomeprazole magnesium (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of VIMOVO or substituted benzimidazoles (<a href="#S4">4</a>)</li>
<li>History of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or other allergic-type reactions after taking aspirin or other NSAIDs (<a href="#S4">4</a>, <a href="#S5.8">5.8</a>, <a href="#S5.9">5.9</a>, <a href="#S5.13">5.13</a>)</li>
<li>Use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery (<a href="#S4">4</a>, <a href="#S5.1">5.1</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li> Serious and potentially fatal cardiovascular (CV) thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. Patients with known CV disease/risk factors may be at greater risk (<a href="#S5.1">5.1</a>)</li>
<li>New onset or worsening of pre-existing <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Blood pressure should be monitored closely during treatment with VIMOVO (<a href="#S5.2">5.2</a>, <a href="#S7.1">7.1</a>, <a href="#S7.6">7.6</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. VIMOVO should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (<a href="#S5.3">5.3</a>)</li>
<li>Serious gastrointestinal (GI) adverse events, which can be fatal. The risk is greater in patients with a prior history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease or GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and in patients at high risk for GI events, especially the elderly. VIMOVO should be used with caution in these patients (<a href="#S5.4">5.4</a>, <a href="#S8.5">8.5</a>)</li>
<li>Symptomatic response to esomeprazole does not preclude the presence of <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">gastric malignancy</span> (<a href="#S5.4">5.4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="192667" conceptname="Atrophic gastritis">Atrophic gastritis</span> has been noted on biopsy with long-term omeprazole therapy (<a href="#S5.4">5.4</a>)</li>
<li>Treatment should be withdrawn when active and clinically significant <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from any source occurs (<a href="#S5.5">5.5</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">Renal papillary necrosis</span> and other <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span> with long-term use. Use VIMOVO with caution in the elderly, those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver dysfunction, and those taking diuretics, ACE-inhibitors or angiotensin II receptor antagonists. <span class="product-label-link" type="condition" conceptid="4102631" conceptname="Acute interstitial nephritis">Acute interstitial nephritis</span> has been observed in patients taking PPIs. Not recommended for patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (<a href="#S2">2</a>, <a href="#S5.6">5.6</a>, <a href="#S5.7">5.7</a>, <a href="#S5.16">5.16</a>, <a href="#S7.1">7.1</a>, <a href="#S7.6">7.6</a>, <a href="#S8.7">8.7</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span>. Do not use VIMOVO in patients with the aspirin triad (<a href="#S5.8">5.8</a>)</li>
<li>Serious skin adverse reactions such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, which can be fatal and can occur without warning. Discontinue VIMOVO at first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (<a href="#S5.9">5.9</a>)</li>
<li>Elevated liver enzymes and, rarely, severe hepatic reactions. Discontinue use immediately if abnormal liver enzymes persist or worsen (<a href="#S5.11">5.11</a>, <a href="#S8.6">8.6</a>, <a href="#S12.3">12.3</a>)</li>
<li>Should be avoided in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (e.g., Child-Pugh C) (<a href="#S2">2</a>, <a href="#S5.11">5.11</a>, <a href="#S8.6">8.6</a>, <a href="#S12.3">12.3</a>)Cyanocobalamin (vitamin B-12) Deficiency:  Daily long-term use (e.g., longer than 3 years) may lead to <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span> or a deficiency of cyanocobalamin. (<a href="#S5.17">5.17</a>)</li>
<li>Proton pump inhibitor (PPI) therapy may be associated with increased risk of <span class="Italics">Clostridium difficile </span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. (<a href="#S5.18">5.18</a>)</li>
<li>Avoid concomitant use of esomeprazole with clopidogrel (<a href="#S5.19">5.19</a>)</li>
<li>Long-term and multiple daily dose PPI therapy is associated with an increased risk for <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>-related <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> of the hip, wrist or spine (<a href="#S5.20">5.20</a>)</li>
<li>Interactions with diagnostic investigations for Neuroendocrine Tumors: Increases in intragastric pH may result in <span class="product-label-link" type="condition" conceptid="4245637" conceptname="Hypergastrinemia">hypergastrinemia</span>, enterochromaffin-like cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, and increased Chromogranin A levels which may interfere with diagnostic investigations for neuroendocrine tumors. (<a href="#S5.22">5.22</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span> has been reported rarely with prolonged treatment with PPIs (<a href="#S5.23">5.23</a>)</li>
<li>Avoid concomitant use of VIMOVO with St John's Wort or rifampin due to the potential reduction in esomeprazole levels. (<a href="#S5.24">5.24</a>, <a href="#S7.16">7.16</a>)</li>
<li>Fetal toxicity: avoid drug starting at 30 weeks gestation (<a href="#S5.10">5.10</a>, <a href="#S8.1">8.1</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">Most common adverse reactions in clinical trials (&gt;5%):  <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (<a href="#S6.1">6.1</a>)<br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Horizon Pharma USA, Inc. at 1-866-479-6742 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Concomitant use of NSAIDs may reduce the antihypertensive effect of ACE Inhibitors, angiotensin II receptor antagonists, diuretics, and beta-blockers (<a href="#S7.1">7.1</a>, <a href="#S7.6">7.6</a>, <a href="#S7.11">7.11</a>)</li>
<li> As with all NSAIDs caution is advised when cyclosporin is co-administered because of the increased risk of <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>. (<a href="#S7.4">7.4</a>)</li>
<li>Tacrolimus: Concomitant administration of esomeprazole, a component of VIMOVO, and tacrolimus may increase the serum levels of tacrolimus. (<a href="#S7.5">7.5</a>)</li>
<li>Concomitant use of NSAIDs increases lithium plasma levels (<a href="#S7.7">7.7</a>)</li>
<li>Methotrexate: VIMOVO may increase serum levels of methotrexate (<a href="#S7.8">7.8</a>)</li>
<li>Concomitant use of VIMOVO with warfarin may result in increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complications. Monitor for increases in INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (<a href="#S7.9">7.9</a>)</li>
<li> Esomeprazole inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts, erlotinib, digoxin, and mycophenolate mofetil). Patients treated with VIMOVO and digoxin may need to be monitored for increases in <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> (<a href="#S7.14">7.14</a>)</li>
<li>Clopidogrel: esomeprazole, a component of VIMOVO, decreases exposure to the active metabolite of clopidogrel. (<a href="#S7.16">7.16</a>, <a href="#S12.3">12.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span>: VIMOVO should be avoided in patients with severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> (<a href="#S2">2</a>, <a href="#S4">4</a>, <a href="#S5.11">5.11</a>, <a href="#S8.6">8.6</a>, <a href="#S12.3">12.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span>:  VIMOVO is not recommended in patients with moderate or severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (<a href="#S2">2</a>, <a href="#S5.6">5.6</a>, <a href="#S5.7">5.7</a>, <a href="#S8.7">8.7</a>, <a href="#S12.3">12.3</a>)</li>
</ul></div>
<div><div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div><div></div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div><div>
<div></div>
<div></div>
<div></div>
<div></div>
</div></div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 6/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1	INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2	DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4	CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	Cardiovascular Thrombotic Events</a></h2>
<h2><a href="#section-5.2" class="toc">5.2	<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3	<span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> </a></h2>
<h2><a href="#section-5.4" class="toc">5.4	Gastrointestinal Effects — Risk of Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation </a></h2>
<h2><a href="#section-5.5" class="toc">5.5	Active <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6	Renal Effects </a></h2>
<h2><a href="#section-5.7" class="toc">5.7	Advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span> </a></h2>
<h2><a href="#section-5.8" class="toc">5.8	<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span> </a></h2>
<h2><a href="#section-5.9" class="toc">5.9	<span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10	Fetal Toxicity </a></h2>
<h2><a href="#section-5.11" class="toc">5.11	Hepatic Effects </a></h2>
<h2><a href="#section-5.12" class="toc">5.12	Hematological Effects </a></h2>
<h2><a href="#section-5.13" class="toc">5.13	Pre-existing <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> </a></h2>
<h2><a href="#section-5.14" class="toc">5.14	Concomitant NSAID Use</a></h2>
<h2><a href="#section-5.15" class="toc">5.15	Corticosteroid Treatment</a></h2>
<h2><a href="#section-5.16" class="toc">5.16    <span class="product-label-link" type="condition" conceptid="4102631" conceptname="Acute interstitial nephritis">Acute Interstitial Nephritis</span></a></h2>
<h2><a href="#section-5.17" class="toc">5.17	Cyanocobalamin (vitamin B-12) Deficiency</a></h2>
<h2><a href="#section-5.18" class="toc">5.18<span class="Italics"> Clostridium difficile </span>Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></a></h2>
<h2><a href="#section-5.19" class="toc">5.19	Interaction with Clopidogrel</a></h2>
<h2><a href="#section-5.20" class="toc">5.20    Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span></a></h2>
<h2><a href="#section-5.21" class="toc">5.21	Masking of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></a></h2>
<h2><a href="#section-5.22" class="toc">5.22	Laboratory Tests</a></h2>
<h2><a href="#section-5.23" class="toc">5.23	<span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span></a></h2>
<h2><a href="#section-5.24" class="toc">5.24	Concomitant use of St John's Wort or Rifampin with VIMOVO</a></h2>
<h2><a href="#section-5.25" class="toc">5.25 	Concomitant use of VIMOVO with Methotrexate</a></h2>
<h1><a href="#section-6" class="toc">6	ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience with VIMOVO</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Clinical Trials Experience with Naproxen and Other NSAIDs</a></h2>
<h2><a href="#section-6.3" class="toc">6.3	Clinical Trials Experience with Esomeprazole Magnesium</a></h2>
<h2><a href="#section-6.4" class="toc">6.4	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc"> 7	DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	ACE-inhibitors/Angiotensin II Receptor Antagonists</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Aspirin</a></h2>
<h2><a href="#section-7.3" class="toc">7.3	Cholestyramine </a></h2>
<h2><a href="#section-7.4" class="toc">7.4 	Cyclosporin</a></h2>
<h2><a href="#section-7.5" class="toc">7.5	Tacrolimus</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 	Diuretics</a></h2>
<h2><a href="#section-7.7" class="toc">7.7	Lithium</a></h2>
<h2><a href="#section-7.8" class="toc">7.8	Methotrexate </a></h2>
<h2><a href="#section-7.9" class="toc">7.9 	Anticoagulants</a></h2>
<h2><a href="#section-7.10" class="toc">7.10 	Selective Serotonin Reuptake Inhibitors (SSRIs) </a></h2>
<h2><a href="#section-7.11" class="toc">7.11	Other Information Concerning Drug Interactions</a></h2>
<h2><a href="#section-7.12" class="toc">7.12 	Interactions With Investigations of Neuroendocrine Tumors</a></h2>
<h2><a href="#section-7.13" class="toc">7.13	Drug/Laboratory Test Interaction</a></h2>
<h2><a href="#section-7.14" class="toc">7.14	Interactions Related to Absorption</a></h2>
<h2><a href="#section-7.15" class="toc">7.15	Antiretroviral Agents</a></h2>
<h2><a href="#section-7.16" class="toc">7.16	Effects on Hepatic Metabolism/Cytochrome P-450 pathways</a></h2>
<h2><a href="#section-7.17" class="toc">7.17	Other Pharmacokinetic-based Interactions</a></h2>
<h1><a href="#section-8" class="toc">8	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1	Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3	Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4	Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5	Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6	<span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7	<span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.8	Females and Males of Reproductive Potential</a></h2>
<h1><a href="#section-9" class="toc">10	OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11	DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1	Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2	Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3	Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13	NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2	Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 	CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17	PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
<p class="First"><span class="Bold">Cardiovascular Risk</span></p>
<ul class="Square">
<li>Non-Steroidal Anti-inflammatory Drugs (NSAIDs), a component of VIMOVO, may cause an increased risk of serious cardiovascular thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk [see<span class="Italics"><a href="#S5.1"> Warnings and Precautions (5.1)</a></span>].</li>
<li>VIMOVO is contraindicated for the treatment of peri-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery [see<span class="Italics"><a href="#S4"> Contraindications (4)</a>,</span> and<span class="Italics"><a href="#S5.1"> Warnings and Precautions (5.1)</a></span>].</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.2"></a><p></p>
<p class="First"><span class="Bold">Gastrointestinal Risk</span></p>
<ul class="Square"><li>NSAIDs, including naproxen, a component of VIMOVO, cause an increased risk of serious gastrointestinal adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events [see<span class="Italics"><a href="#S5.4"> Warnings and Precautions (5.4)</a></span>]<span class="Italics">.</span>
</li></ul>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1	INDICATIONS AND USAGE</h1>
<p class="First">VIMOVO is a combination product that contains naproxen and esomeprazole. It is indicated for the relief of signs and symptoms of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>, <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> and <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">ankylosing spondylitis</span> and to decrease the risk of developing <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span> in patients at risk of developing NSAID-associated <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span>. VIMOVO is not recommended for initial treatment of <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products<span class="Italics">.</span> Controlled studies do not extend beyond 6 months.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2	DOSAGE AND ADMINISTRATION</h1>
<p class="First">Carefully consider the potential benefits and risks of VIMOVO and other treatment options before deciding to use VIMOVO. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. VIMOVO does not allow for administration of a lower daily dose of esomeprazole. If a dose of esomeprazole lower than a total daily dose of 40 mg is more appropriate, a different treatment should be considered.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span>, <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span> and <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">Ankylosing Spondylitis</span></span></p>
<p>The dosage is one tablet twice daily of VIMOVO 375 mg naproxen and 20 mg of esomeprazole or 500 mg naproxen and 20 mg of esomeprazole.</p>
<p>The tablets are to be swallowed whole with liquid. Do not split, chew, crush or dissolve the tablet. VIMOVO is to be taken at least 30 minutes before meals.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<p class="First"><span class="Bold Italics">Geriatric Patients</span></p>
<p>Studies indicate that although total plasma concentration of naproxen is unchanged, the unbound plasma fraction of naproxen is increased in the elderly. Use caution when high doses are required and some adjustment of dosage may be required in elderly patients. As with other drugs used in the elderly use the lowest effective dose [see <span class="Italics"><a href="#S8.5">Use in Specific Populations (8.5)</a></span> and<span class="Italics"><a href="#S12.3"> Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3"></a><p></p>
<p class="First"><span class="Bold Italics">Patients With Moderate to Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>Naproxen-containing products are not recommended for use in patients with moderate to severe or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance &lt;30 mL/min) [see <span class="Italics"><a href="#S5.6">Warnings and Precautions (5.6</a>, <a href="#S5.7">5.7)</a></span> and<span class="Italics"><a href="#S8.7"> Use in Specific Populations (8.7)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></span></p>
<p>Monitor patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> closely and consider a possible dose reduction based on the naproxen component of VIMOVO.</p>
<p>VIMOVO should be avoided in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [see <span class="Italics"><a href="#S5.11">Warnings and Precautions (5.11)</a>, <a href="#S8.6">Use in Specific Populations (8.6)</a></span> and<span class="Italics"><a href="#S12.3"> Clinical Pharmacology (12.3)</a></span>]<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.5"></a><p></p>
<p class="First"><span class="Bold Italics">Pediatric Patients</span></p>
<p>The safety and efficacy of VIMOVO in children younger than 18 years has not been established. VIMOVO is therefore not recommended for use in children.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Oval, yellow, delayed release tablets for oral administration containing either:</p>
<ul class="Disc">
<li>375 mg enteric coated naproxen and 20 mg esomeprazole (as magnesium trihydrate) tablets printed with 375/20 in black, or</li>
<li>500 mg enteric coated naproxen and 20 mg esomeprazole (as magnesium trihydrate) tablets printed with 500/20 in black.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4	CONTRAINDICATIONS</h1>
<p class="First">VIMOVO is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to naproxen, esomeprazole magnesium, substituted benzimidazoles, or to any of the excipients.</p>
<p>VIMOVO is contraindicated in patients who have experienced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients [see<span class="Italics"><a href="#S5.8"> Warnings and Precautions (5.8</a>, <a href="#S5.13">5.13)</a></span>]. VIMOVO is also contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to substituted benzimidazoles or to any component of the formulation including omeprazole.  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> to esomeprazole may include <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="4102631" conceptname="Acute interstitial nephritis">acute interstitial nephritis</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> [see <span class="Italics"><a href="#S6">Adverse Reactions (6)</a></span>].</p>
<p>VIMOVO is contraindicated for the treatment of peri-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery [see<span class="Italics"><a href="#S5.1"> Warnings and Precautions (5.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	Cardiovascular Thrombotic Events</h2>
<p class="First">Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. All NSAIDS, both COX-2 selective and nonselective, may have a similar risk. Patients with known CV disease or risk factors for CV disease may be at greater risk. To minimize the potential risk for an adverse CV event in patients treated with an NSAID, the lowest effective dose should be used for the shortest duration possible. Physicians and patients should remain alert for the development of such events, even in the absence of previous CV symptoms. Patients should be informed about the signs and/or symptoms of serious CV events and the steps to take if they occur.</p>
<p>There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use.</p>
<p>Two large, controlled, clinical trials of a COX-2 selective NSAID for the treatment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the first 10–14 days following CABG surgery found an increased incidence of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> [see<span class="Italics"><a href="#S4"> Contraindications (4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">NSAIDs, including naproxen, a component of VIMOVO, can lead to onset of new <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or worsening of pre-existing <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, either of which may contribute to the increased incidence of CV events. Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. NSAIDs should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Blood pressure (BP) should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy [see<span class="Italics"><a href="#S7.1"> Drug Interactions (7.1</a>, <a href="#S7.6">7.6)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	<span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> have been observed in some patients taking NSAIDs and should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	Gastrointestinal Effects — Risk of Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation </h2>
<p class="First">NSAIDs, including naproxen, a component of VIMOVO, can cause serious gastrointestinal (GI) adverse events including <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach, small intestine, or large intestine, which can be fatal. While VIMOVO has been shown to significantly decrease the occurrence of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span> compared to naproxen alone, ulceration and associated complications can still occur.</p>
<p>These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, gross <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3–6 months, and in about 2–4% of patients treated for one year. These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short-term therapy is not without risk. The utility of periodic laboratory monitoring has not been demonstrated, nor has it been adequately assessed.</p>
<p>VIMOVO should be prescribed with caution in those with a prior history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. Patients with a prior history of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> and/or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> who use NSAIDs have a greater than 10-fold increased risk of developing a <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI bleed</span> compared to patients with neither of these risk factors. Other factors that increase the risk for GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants or antiplatelets (including low-dose aspirin), longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. Most spontaneous reports of fatal GI events are in elderly or debilitated patients, and therefore special care should be taken in treating this population.</p>
<p>To minimize the potential risk for an adverse GI event in patients treated with an NSAID or NSAID-containing product, the lowest effective dose should be used for the shortest possible duration. Patients and physicians should remain alert for signs and symptoms of GI ulceration and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during NSAID therapy and promptly initiate additional evaluation and treatment if a serious GI adverse event is suspected. This should include discontinuation of the NSAID until a serious GI adverse event is ruled out. For high risk patients, alternate therapies that do not involve NSAIDs should be considered.</p>
<p>Epidemiological studies of the case-control and cohort design have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. In two studies, concurrent use of an NSAID, COX-2 inhibitor, or aspirin potentiated the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> [see <span class="Italics"><a href="#S7.2">Drug Interactions (7.2</a>, <a href="#S7.10">7.10)</a></span>]. Although these studies focused on upper <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> at other sites cannot be ruled out.</p>
<p>NSAIDs should be given with care to patients with a history of <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span> (<span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, Crohn's disease) as their condition may be exacerbated.</p>
<p>Gastrointestinal symptomatic response to therapy with VIMOVO does not preclude the presence of <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">gastric malignancy</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="192667" conceptname="Atrophic gastritis">Atrophic gastritis</span> has been noted occasionally in gastric corpus biopsies from patients treated long-term with omeprazole, of which esomeprazole is an enantiomer and a component of VIMOVO.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	Active <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">When active and clinically significant <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from any source occurs in patients receiving VIMOVO, the treatment should be withdrawn.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	Renal Effects </h2>
<p class="First">Long-term administration of NSAIDs has resulted in <span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">renal papillary necrosis</span> and other <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver dysfunction, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span>, those taking diuretics, ACE inhibitors, or angiotensin II receptor antagonists and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7	Advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span> </h2>
<p class="First">No information is available from controlled clinical studies regarding the use of VIMOVO in patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. Therefore, treatment with VIMOVO is not recommended in these patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. If VIMOVO therapy must be initiated, close monitoring of the patient's renal function is advisable and patients should be adequately hydrated [see <span class="Italics"><a href="#S2">Dosage and Administration (2)</a>, <a href="#S8.7">Use in Specific Populations (8.7)</a></span> and <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8	<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span> </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> may occur in patients without known prior exposure to either component of VIMOVO. NSAIDs should not be given to patients with the aspirin triad. This symptom complex typically occurs in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients who experience <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> with or without <span class="product-label-link" type="condition" conceptid="253788" conceptname="Nasal polyp">nasal polyps</span>, or who exhibit severe, potentially fatal <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> after taking aspirin or other NSAIDs [see <span class="Italics"><a href="#S4">Contraindications (4)</a></span>]. Emergency help should be sought in cases where an <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> occurs. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span>, like <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, may have a fatal outcome.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9	<span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First">NSAIDs can cause serious skin adverse events such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, which can be fatal. These serious events may occur without warning. Patients should be informed about the signs and symptoms of serious skin manifestations and use of the drug should be discontinued at the first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10	Fetal Toxicity </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.10.1"></a><p></p>
<p class="First">Starting at 30 weeks gestation, VIMOVO, as with other NSAID-containing products, should be avoided because it may cause premature closure of the ductus arteriosus [see <span class="Italics"><a href="#S8.1">Use in Specific Populations (8.1)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.11"></a><a name="section-5.11"></a><p></p>
<h2>5.11	Hepatic Effects </h2>
<p class="First">Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs including naproxen, a component of VIMOVO. Hepatic abnormalities may be the result of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> rather than direct toxicity. These laboratory abnormalities may progress, may remain essentially unchanged, or may be transient with continued therapy. The SGPT (ALT) test is probably the most sensitive indicator of liver dysfunction. Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, including <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and fatal fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span> and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, some of them with fatal outcomes, have been reported.</p>
<p>A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of more severe hepatic reaction while on therapy with VIMOVO.</p>
<p>If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, etc.), VIMOVO should be discontinued.</p>
<p>Chronic <span class="product-label-link" type="condition" conceptid="201612" conceptname="Alcoholic liver damage">alcoholic liver disease</span> and probably other diseases with decreased or abnormal plasma proteins (albumin) reduce the total plasma concentration of naproxen, but the plasma concentration of unbound naproxen is increased. Caution is advised when high doses are required and some adjustment of dosage may be required in these patients. It is prudent to use the lowest effective dose for the shortest possible duration of adequate treatment.</p>
<p>VIMOVO should be avoided in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [see <span class="Italics"><a href="#S2">Dosage and Administration (2)</a></span>, <span class="Italics"><a href="#S8.6">Use in Specific Populations (8.6)</a>,</span> and<span class="Italics"><a href="#S12.3"> Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.12"></a><a name="section-5.12"></a><p></p>
<h2>5.12	Hematological Effects </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> is sometimes seen in patients receiving NSAIDs. This may be due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.</p>
<p>NSAIDs inhibit platelet aggregation and have been shown to prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients receiving VIMOVO who may be adversely affected by alterations in platelet function, such as those with <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorders</span> or patients receiving anticoagulants or antiplatelets, should be carefully monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.13"></a><a name="section-5.13"></a><p></p>
<h2>5.13	Pre-existing <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> </h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> may have aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. The use of aspirin in patients with aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has been associated with severe <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, which can be fatal. Since cross reactivity, including <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, VIMOVO should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with pre-existing <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.14"></a><a name="section-5.14"></a><p></p>
<h2>5.14	Concomitant NSAID Use</h2>
<p class="First">VIMOVO contains naproxen as one of its active ingredients. It should not be used with other naproxen-containing products since they all circulate in the plasma as the naproxen anion.</p>
<p>The concomitant use of VIMOVO with any dose of a non-aspirin NSAID should be avoided due to the potential for increased risk of adverse reactions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.15"></a><a name="section-5.15"></a><p></p>
<h2>5.15	Corticosteroid Treatment</h2>
<p class="First">VIMOVO cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids and the patient should be observed closely for any evidence of adverse effects, including <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> and exacerbation of symptoms of <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.16"></a><a name="section-5.16"></a><p></p>
<h2>5.16    <span class="product-label-link" type="condition" conceptid="4102631" conceptname="Acute interstitial nephritis">Acute Interstitial Nephritis</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="4102631" conceptname="Acute interstitial nephritis">Acute interstitial nephritis</span> has been observed in patients taking PPIs including VIMOVO.  <span class="product-label-link" type="condition" conceptid="4102631" conceptname="Acute interstitial nephritis">Acute interstitial nephritis</span> may occur at any point during PPI therapy and is generally attributed to an idiopathic <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>.  Discontinue VIMOVO if <span class="product-label-link" type="condition" conceptid="4102631" conceptname="Acute interstitial nephritis">acute interstitial nephritis</span> develops [see <span class="Italics"><a href="#S4">Contraindications (4)</a></span>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.17"></a><a name="section-5.17"></a><p></p>
<h2>5.17	Cyanocobalamin (vitamin B-12) Deficiency</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Daily treatment with any acid-suppressing medications over a long period of time (e.g., longer than 3   years) may lead to <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span> of cyanocobalamin (vitamin B-12) caused by hypo-or <span class="product-label-link" type="condition" conceptid="193804" conceptname="Achlorhydria">achlorhydria</span>. Rare reports of cyanocobalamin deficiency occurring with acid-suppressing therapy have been reported in the literature.  This diagnosis should be considered if clinical symptoms consistent with cyanocobalamin deficiency are observed.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.18"></a><a name="section-5.18"></a><p></p>
<h2>5.18<span class="Italics"> Clostridium difficile </span>Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First">Published observational studies suggest that proton pump inhibitor (PPI) therapy like VIMOVO may be associated with an increased risk of <span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, especially in hospitalized patients. This diagnosis should be considered for <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> that does not improve [see <span class="Italics"><a href="#S6.2">Adverse Reactions (6.2)</a></span>]<span class="Italics">.</span></p>
<p>Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. [see <span class="Italics"><a href="#S2">Dosage and Administration (2)</a></span>]<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.19"></a><a name="section-5.19"></a><p></p>
<h2>5.19	Interaction with Clopidogrel</h2>
<p class="First">Avoid concomitant use of esomeprazole with clopidogrel. Clopidogrel is a prodrug. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. The metabolism of clopidogrel to its active metabolite can be impaired by use with concomitant medications, such as esomeprazole, that inhibit CYP2C19 activity. Concomitant use of clopidogrel with 40 mg esomeprazole reduces the pharmacological activity of clopidogrel. When using esomeprazole, a component of VIMOVO, consider alternative anti-platelet therapy [<span class="Italics">see <a href="#S7.16">Drug Interactions (7.16)</a> and <a href="#S12.3">Pharmacokinetics (12.3)</a></span>]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.20"></a><a name="section-5.20"></a><p></p>
<h2>5.20    Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span></h2>
<p class="First">Several published observational studies suggest that PPI therapy may be associated with an increased risk for <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>-related <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> of the hip, wrist, or spine. The risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> was increased in patients who received high-dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Patients at risk for <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>-related <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> should be managed according to the established treatment guidelines. [see <span class="Italics"><a href="#S2">Dosage and Administration (2)</a></span> and <span class="Italics"><a href="#S6.2">Adverse Reactions (6.2)</a></span>].</p>
<p>VIMOVO (a combination PPI/NSAID) is approved for use twice a day and does not allow for administration of a lower daily dose of the PPI. [see <span class="Italics"><a href="#S2">Dosage and Administration (2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.21"></a><a name="section-5.21"></a><p></p>
<h2>5.21	Masking of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></h2>
<p class="First">The pharmacological activity of VIMOVO in reducing <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, noninflammatory painful conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.22"></a><a name="section-5.22"></a><p></p>
<h2>5.22	Laboratory Tests</h2>
<p class="First">Because serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, physicians should monitor for signs or symptoms of GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Patients on long-term treatment with NSAIDs should have their CBC and a chemistry profile checked periodically. If clinical signs and symptoms consistent with liver or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> develop, systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, etc.) or if abnormal liver tests persist or worsen, VIMOVO should be discontinued.</p>
<p>Patients with initial hemoglobin values of 10 g or less who are to receive long-term therapy should have hemoglobin values determined periodically.</p>
<p>Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors. Providers should temporarily stop esomeprazole treatment at least 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high. If serial tests are performed (e.g. for monitoring), the same commercial laboratory should be used for testing, as reference ranges between tests may vary [see <span class="Italics"><a href="#S12.2">Clinical Pharmacology (12.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.23"></a><a name="section-5.23"></a><p></p>
<h2>5.23	<span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span>, symptomatic and asymptomatic, has been reported rarely in patients treated with PPIs for at least three months, in most cases after a year of therapy. Serious adverse events include <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. In most patients, treatment of <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> required magnesium replacement and discontinuation of the PPI. </p>
<p>For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see <span class="Italics"><a href="#S6.2">Adverse Reactions (6.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.24"></a><a name="section-5.24"></a><p></p>
<h2>5.24	Concomitant use of St John's Wort or Rifampin with VIMOVO</h2>
<p class="First">Drugs that induce CYP2C19 or CYP3A4 (such as St John's Wort or rifampin) can substantially decrease esomeprazole concentrations. Avoid concomitant use of VIMOVO with St John's Wort or rifampin [see <span class="Italics"><a href="#S7.15">Drug Interactions (7.16)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.25"></a><a name="section-5.25"></a><p></p>
<h2>5.25 	Concomitant use of VIMOVO with Methotrexate</h2>
<p class="First">Literature suggests that concomitant use of PPIs with methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities. In high-dose methotrexate administration a temporary withdrawal of the PPI may be considered in some patients [see<span class="Italics"><a href="#S7.8"> Drug Interactions (7.8)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6	ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience with VIMOVO</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The adverse reactions reported below are specific to the clinical trials with VIMOVO.</p>
<p>The safety of VIMOVO was evaluated in clinical studies involving 2317 patients (aged 27 to 90 years) and ranging from 3 to 12 months. Patients received either 500 mg/20 mg of VIMOVO twice daily (n=1157), 500 mg of enteric-coated naproxen twice daily (n=426), or placebo (n=246). The average number of VIMOVO doses taken over 12 months was 696±44.</p>
<p>The table below lists all adverse reactions, regardless of causality, occurring in &gt;2% of patients receiving VIMOVO and higher in the VIMOVO group than control from two clinical studies (Study 1 and Study 2). Both of these studies were randomized, multi-center, double-blind, parallel studies. The majority of patients were female (67%), white (86%). The majority of patients were 50-69 years of age (83%). Approximately one quarter were on low-dose aspirin.</p>
<a name="table1"></a><table width="75%">
<caption><span>Table 1:  Adverse Reactions<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> in Study 1 and Study 2 (endoscopic studies)</span></caption>
<col align="left" valign="top" width="33%">
<col align="left" valign="top" width="34%">
<col align="left" valign="top" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Preferred term</th>
<th class="Rrule" align="center">VIMOVO 500 mg/20 mg twice daily<br>(n=428)<br>%</th>
<th class="Rrule" align="center">EC-Naproxen<br>500 mg twice daily<br>(n=426)<br>%</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>reported in &gt;2% of patients and higher in the VIMOVO group than control</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">Gastritis</span></td>
<td class="Rrule" align="left">17</td>
<td class="Rrule" align="left">14</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="left">6</td>
<td class="Rrule" align="left">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td class="Rrule" align="left">5</td>
<td class="Rrule" align="left">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td class="Rrule" align="left">4</td>
<td class="Rrule" align="left">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="left">3</td>
<td class="Rrule" align="left">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td class="Rrule" align="left">2</td>
<td class="Rrule" align="left">1</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span></td>
<td class="Rrule" align="left">2</td>
<td class="Rrule" align="left">1</td>
</tr>
</tbody>
</table>
<p>In Study 1 and Study 2, patients taking VIMOVO had fewer premature discontinuations due to adverse reactions compared to patients taking enteric-coated naproxen alone (7.9% vs. 12.5% respectively). The most common reasons for discontinuations due to adverse events in the VIMOVO treatment group were <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">upper abdominal pain</span> (1.2%, n=5), <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> (0.7%, n=3) and erosive <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span> (0.7%, n=3). Among patients receiving enteric-coated naproxen, the most common reasons for discontinuations due to adverse events were <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> 5.4% (n=23), <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> 2.8% (n=12) and <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">upper abdominal pain</span> 1.2% (n=5). The proportion of patients discontinuing treatment due to any upper gastrointestinal adverse events (including <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span>) in patients treated with VIMOVO was 4% compared to 12% for patients taking enteric-coated naproxen.</p>
<p>The table below lists all adverse reactions, regardless of causality, occurring in &gt;2% of patients and higher in the VIMOVO group than placebo from 2 clinical studies conducted in patients with <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> of the knee (Study 3 and Study 4).</p>
<a name="table2"></a><table width="75%">
<caption><span>Table 2:  Adverse Reactions<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a> in Study 3 and Study 4</span></caption>
<col align="left" valign="top" width="33%">
<col align="left" valign="top" width="34%">
<col align="left" valign="top" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Preferred term</th>
<th class="Rrule" align="center">VIMOVO 500 mg/20 mg twice daily<br>(n=490)<br>%</th>
<th class="Rrule" align="center">Placebo<br>(n=246)<br>%</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>reported in &gt;2% of patients and higher in the VIMOVO group than placebo</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="left">6</td>
<td class="Rrule" align="left">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal Pain Upper</span></td>
<td class="Rrule" align="left">4</td>
<td class="Rrule" align="left">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="left">4</td>
<td class="Rrule" align="left">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="left">3</td>
<td class="Rrule" align="left">2</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span></td>
<td class="Rrule" align="left">3</td>
<td class="Rrule" align="left">1</td>
</tr>
</tbody>
</table>
<p>The percentage of subjects who withdrew from the VIMOVO treatment group in these studies due to treatment-emergent adverse events was 7%. There were no preferred terms in which more than 1% of subjects withdrew from any treatment group.</p>
<p>The long-term safety of VIMOVO was evaluated in an open-label clinical trial of 239 patients, of which 135 patients received 500 mg/20 mg of VIMOVO for 12 months. There were no differences in frequency or types of adverse reactions seen in the long-term safety study compared to shorter-term treatment in the randomized controlled studies.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Clinical Trials Experience with Naproxen and Other NSAIDs</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.1"></a><p></p>
<p class="First"><span class="Underline">In patients taking naproxen in clinical trials, the most frequent reported adverse experiences in approximately 1% to 10% of patients are:</span></p>
<p><span class="Italics">Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span></p>
<p><span class="Italics">Central Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><span class="Italics">Dermatologic: </span><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruptions</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span></p>
<p><span class="Italics">Special Senses: </span><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, hearing disturbances</p>
<p><span class="Italics">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span></p>
<p><span class="Italics">General:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.2"></a><p></p>
<p class="First"><span class="Underline">In patients taking NSAIDs, the following adverse experiences have also been reported in approximately 1% to 10% of patients.</span></p>
<p><span class="Italics">Gastrointestinal:</span> gross <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>/perforation, GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> (gastric/duodenal), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
<p><span class="Italics">General:</span> abnormal renal function, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, elevated liver enzymes, increased <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.3"></a><p></p>
<p class="First"><span class="Underline">The following are additional adverse experiences reported in &lt;1% of patients taking naproxen during clinical trials.</span></p>
<p><span class="Italics">Gastrointestinal:</span><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span></p>
<p><span class="Italics">Hepatobiliary: </span><span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span></p>
<p><span class="Italics">Hemic and Lymphatic: </span><span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span></p>
<p><span class="Italics">Nervous System: </span>inability to concentrate</p>
<p><span class="Italics">Dermatologic: </span><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.4"></a><p></p>
<p class="First"><span class="Underline">In patients taking NSAIDs, the following adverse experiences hav also been reported in &lt;1% of patients.</span></p>
<p><span class="Italics">Body as a Whole: </span><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, appetite changes, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></p>
<p><span class="Italics">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span></p>
<p><span class="Italics">Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span></p>
<p><span class="Italics">Hepatobiliary: </span><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span></p>
<p><span class="Italics">Hemic and Lymphatic: </span><span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span></p>
<p><span class="Italics">Metabolic and Nutritional: </span>weight changes</p>
<p><span class="Italics">Nervous System: </span><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span></p>
<p><span class="Italics">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span></p>
<p><span class="Italics">Dermatologic: </span><span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span></p>
<p><span class="Italics">Special Senses: </span><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span></p>
<p><span class="Italics">Urogenital: </span><span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>/<span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.3"></a><a name="section-6.3"></a><p></p>
<h2>6.3	Clinical Trials Experience with Esomeprazole Magnesium</h2>
<p class="First">Additional adverse reactions that were reported as possibly or probably related to NEXIUM with an incidence of &lt;1% are listed below by body system:</p>
<p><span class="Italics">Body as a Whole: </span><span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdomen enlarged</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">substernal chest pain</span>, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, flu-like disorder, <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span></p>
<p><span class="Italics">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span></p>
<p><span class="Italics">Endocrine: </span><span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span></p>
<p><span class="Italics">Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4093447" conceptname="Dysplasia">dysplasia</span> GI, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="31610" conceptname="Disorder of esophagus">esophageal disorder</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI hemorrhage</span>, GI symptoms not otherwise specified, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccup</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, mouth disorder, pharynx disorder, <span class="product-label-link" type="condition" conceptid="79069" conceptname="Disorder of rectum">rectal disorder</span>, serum gastrin increased, <span class="product-label-link" type="condition" conceptid="432941" conceptname="Disorder of tongue">tongue disorder</span>, <span class="product-label-link" type="condition" conceptid="4217627" conceptname="Edema of the tongue">tongue edema</span>, <span class="product-label-link" type="condition" conceptid="4160872" conceptname="Recurrent aphthous ulcer">ulcerative stomatitis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
<p><span class="Italics">Hearing:</span> <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">earache</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span></p>
<p><span class="Italics">Hematologic: </span><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4195171" conceptname="Normocytic hypochromic anemia">anemia hypochromic</span>, cervical <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></p>
<p><span class="Italics">Hepatic: </span><span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">bilirubinemia</span>, <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">hepatic function abnormal</span>, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> increased, SGPT increased</p>
<p><span class="Italics">Metabolic/Nutritional: </span><span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, increased alkaline phosphatase, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, vitamin B12 deficiency, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increase</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span></p>
<p><span class="Italics">Musculoskeletal: </span><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis aggravated</span>, <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia syndrome</span>, <span class="product-label-link" type="condition" conceptid="199860" conceptname="Hernia of abdominal cavity">hernia</span>, <span class="product-label-link" type="condition" conceptid="255348" conceptname="Polymyalgia rheumatica">polymyalgia rheumatica</span></p>
<p><span class="Italics">Nervous System/Psychiatric: </span><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, appetite increased, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression aggravated</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine aggravated</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorder</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field defect</span></p>
<p><span class="Italics">Reproductive: </span><span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">menstrual disorder</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span></p>
<p><span class="Italics">Respiratory: </span><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma aggravated</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">larynx edema</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span></p>
<p><span class="Italics">Skin and Appendages: </span><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="200169" conceptname="Pruritus ani">pruritus ani</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculo-papular, <span class="product-label-link" type="condition" conceptid="135032" conceptname="Dermatitis due to substances taken internally">skin inflammation</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating increased</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
<p><span class="Italics">Special Senses: </span><span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, <span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">parosmia</span>, <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">taste loss</span></p>
<p><span class="Italics">Urogenital: </span>abnormal urine, <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, micturition frequency, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span>, genital <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span></p>
<p><span class="Italics">Visual: </span><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="4265433" conceptname="Visual impairment">vision abnormal</span></p>
<p>The following potentially clinically significant laboratory changes in clinical trials, irrespective of relationship to esomeprazole, were reported in ≤ 1% of patients: increased creatinine, uric acid, total bilirubin, alkaline phosphatase, ALT, AST, hemoglobin, white blood cell count, platelets, serum gastrin, potassium, sodium, thyroxine and thyroid stimulating hormone. Decreases were seen in hemoglobin, white blood cell count, platelets, potassium, sodium, and thyroxine.</p>
<p>Endoscopic findings that were reported as adverse reactions include: <span class="product-label-link" type="condition" conceptid="433516" conceptname="Duodenitis">duodenitis</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="4268622" conceptname="Stricture of esophagus">esophageal stricture</span>, <span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulceration</span>, <span class="product-label-link" type="condition" conceptid="24966" conceptname="Esophageal varices">esophageal varices</span>, <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span>, <span class="product-label-link" type="condition" conceptid="199860" conceptname="Hernia of abdominal cavity">hernia</span>, benign <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> or <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span>, Barrett's esophagus, and <span class="product-label-link" type="condition" conceptid="44791183" conceptname="Pale mucous membrane">mucosal discoloration</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.4"></a><a name="section-6.4"></a><p></p>
<h2>6.4	Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.4.1"></a><p></p>
<p class="First"><span class="Underline">VIMOVO</span></p>
<p><span class="Italics">Body as a Whole</span>: <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">gait disturbance</span></p>
<p><span class="Italics">Gastrointestinal</span>: <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdominal distension</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux</span>, <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">hematochezia</span></p>
<p><span class="Italics">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span> and Procedural Complications</span>: <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">contusion</span>, <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span></p>
<p><span class="Italics">Musculoskeletal and Connective Tissue</span>: <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span></p>
<p><span class="Italics">Urogenital:</span> <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">renal tubular necrosis</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.4.2"></a><p></p>
<p class="First"><span class="Underline">Naproxen</span></p>
<p><span class="Italics">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">menstrual disorders</span></p>
<p><span class="Italics">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span></p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (sometimes fatal, particularly in the elderly), ulceration, and obstruction of the upper or lower gastrointestinal tract, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, exacerbation of <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span> (<span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, Crohn's disease)</p>
<p><span class="Italics">Hepatobiliary: </span><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> (some cases have been fatal)</p>
<p><span class="Italics">Hemic and Lymphatic: </span><span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span></p>
<p><span class="Italics">Metabolic and Nutritional:</span> <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span></p>
<p><span class="Italics">Nervous System:</span> <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, dream abnormalities, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>, cognitive dysfunction, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span></p>
<p><span class="Italics">Respiratory: </span>eosinophilic <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span></p>
<p><span class="Italics">Dermatologic: </span><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>, <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">fixed drug eruption</span>, <span class="product-label-link" type="condition" conceptid="132703" conceptname="Lichen planus">lichen planus</span>, pustular reaction, systemic lupus erythematoses, bullous reactions, including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitive dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reactions</span>, including rare cases resembling <span class="product-label-link" type="condition" conceptid="4177022" conceptname="Erythropoietic protoporphyria">porphyria cutanea tarda</span> (<span class="product-label-link" type="condition" conceptid="4316363" conceptname="Pseudoporphyria">pseudoporphyria</span>) or <span class="product-label-link" type="condition" conceptid="4246290" conceptname="Epidermolysis bullosa">epidermolysis bullosa</span>. If skin fragility, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span> or other symptoms suggestive of <span class="product-label-link" type="condition" conceptid="4316363" conceptname="Pseudoporphyria">pseudoporphyria</span> occur, treatment should be discontinued and the patient monitored.</p>
<p><span class="Italics">Special Senses: </span>hearing impairment, <span class="product-label-link" type="condition" conceptid="378752" conceptname="Corneal opacity">corneal opacity</span>, <span class="product-label-link" type="condition" conceptid="435269" conceptname="Optic papillitis">papillitis</span>, retrobulbar <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>, <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span></p>
<p><span class="Italics">Urogenital: </span>glomerular <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>, <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">renal papillary necrosis</span>, raised serum creatinine</p>
<p><span class="Italics">Reproduction (female): </span><span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.4.3"></a><p></p>
<p class="First"><span class="Underline">Esomeprazole Magnesium</span></p>
<p><span class="Italics">Blood and Lymphatic:</span> <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span></p>
<p><span class="Italics">Eye: </span><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span></p>
<p><span class="Italics">Gastrointestinal: </span> <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, microscopic <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span></p>
<p><span class="Italics">Hepatobiliary: </span><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> with or without <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span></p>
<p><span class="Italics">Immune System: </span><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>/<span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span>: </span><span class="product-label-link" type="condition" conceptid="193133" conceptname="Gastrointestinal candidiasis">GI candidiasis</span>,<span class="Italics"> Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></p>
<p><span class="Italics">Metabolism and Nutritional Disorders: </span> <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, with or without <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> and/or <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span></p>
<p><span class="Italics">Musculoskeletal and Connective Tissue: </span><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span></p>
<p><span class="Italics">Nervous System: </span><span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span></p>
<p><span class="Italics">Psychiatric: </span><span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span></p>
<p><span class="Italics">Renal and Urinary:</span> interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span></p>
<p><span class="Italics">Reproductive System and Breast<span class="Bold">: </span></span> <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span></p>
<p><span class="Italics">Respiratory, Thoracic, and Mediastinal: </span><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span></p>
<p><span class="Italics">Skin and Subcutaneous Tissue: </span><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (some fatal)</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1> 7	DRUG INTERACTIONS</h1>
<p class="First">Several studies conducted with VIMOVO have shown no interaction between the two components, naproxen and esomeprazole.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	ACE-inhibitors/Angiotensin II Receptor Antagonists</h2>
<p class="First">Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors and angiotensin II receptor antagonists. NSAIDs may also increase the risk of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> associated with the use of ACE-inhibitors or angiotensin II receptor antagonists. Monitor renal function closely in patients taking VIMOVO concomitantly with ACE-inhibitors or angiotensin II receptor antagonists who are elderly, volume-depleted, or with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> [see <span class="Italics"><a href="#S8.5">Use in Specific Populations (8.5</a>, <a href="#S8.7">8.7</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Aspirin</h2>
<p class="First">VIMOVO can be administered with low-dose aspirin (≤325 mg/day) therapy. The concurrent use of aspirin and VIMOVO may increase the risk of serious adverse events [see<span class="Italics"><a href="#S5.1"> Warnings and Precautions (5.1</a>, <a href="#S5.4">5.4)</a>, <a href="#S6">Adverse Reactions (6)</a>,</span> and<span class="Italics"><a href="#S14"> Clinical Studies (14)</a></span>]<span class="Italics">.</span></p>
<p>When naproxen is administered with doses of aspirin (&gt;1 gram/day), its protein binding is reduced. The clinical significance of this interaction is not known. However, as with other NSAIDs, concomitant administration of naproxen and aspirin is not generally recommended because of the potential of increased adverse effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3	Cholestyramine </h2>
<p class="First">As with other NSAIDs, concomitant administration of cholestyramine can delay the absorption of naproxen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4 	Cyclosporin</h2>
<p class="First">As with all NSAIDs caution is advised when cyclosporin is co-administered because of the increased risk of <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.5"></a><a name="section-7.5"></a><p></p>
<h2>7.5	Tacrolimus</h2>
<p class="First">Concomitant administration of esomeprazole, a component of VIMOVO, and tacrolimus may increase the serum levels of tacrolimus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.6"></a><a name="section-7.6"></a><p></p>
<h2>7.6 	Diuretics</h2>
<p class="First">Clinical studies, as well as postmarketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, the patient should be observed closely both for signs of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, as well as to monitor to assure diuretic efficacy [see <span class="Italics"><a href="#S5.6">Warnings and Precautions (5.6</a>, <a href="#S5.7">5.7)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.7"></a><a name="section-7.7"></a><p></p>
<h2>7.7	Lithium</h2>
<p class="First">NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%. These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID. Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.8"></a><a name="section-7.8"></a><p></p>
<h2>7.8	Methotrexate </h2>
<p class="First">NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model. This may indicate that they could enhance the toxicity of methotrexate. Caution should be used when NSAIDs are administered concomitantly with methotrexate.</p>
<p>Case reports, published population pharmacokinetic studies, and retrospective analyses suggest that concomitant administration of PPIs and methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate. However, no formal drug interaction studies of methotrexate with PPIs have been conducted [<span class="Italics">see <a href="#S5.25">Warnings and Precautions (5.25)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.9"></a><a name="section-7.9"></a><p></p>
<h2>7.9 	Anticoagulants</h2>
<p class="First">Naproxen decreases platelet aggregation and may prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>. In addition, because warfarin and NSAIDs are highly protein bound, the free fraction of warfarin and naproxen may increase substantially in some patients.</p>
<p>Concomitant use of VIMOVO and anticoagulants (such as warfarin, dicumarol and heparin) may result in increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complications.</p>
<p>The effects of warfarin and NSAIDs on GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> are synergistic, such that users of both drugs together have a risk of serious GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> higher than users of either drug alone.</p>
<p>Post-marketing reports of changes in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> measures have been reported among patients on concomitant warfarin and esomeprazole therapy. Increases in INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time may lead to abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.10"></a><a name="section-7.10"></a><p></p>
<h2>7.10 	Selective Serotonin Reuptake Inhibitors (SSRIs) </h2>
<p class="First">There is an increased risk of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> when selective serotonin reuptake inhibitors (SSRIs) are combined with NSAIDs including COX-2 selective inhibitors. Caution should be used when NSAIDs are administered concomitantly with SSRIs [see <span class="Italics"><a href="#S5.4">Warnings and Precautions (5.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.11"></a><a name="section-7.11"></a><p></p>
<h2>7.11	Other Information Concerning Drug Interactions</h2>
<p class="First">Naproxen is highly bound to plasma albumin; it thus has a theoretical potential for interaction with other albumin-bound drugs such as sulphonylureas, hydantoins, and other NSAIDs. Patients simultaneously receiving VIMOVO and a hydantoin, sulphonamide or sulphonylurea should be observed for adjustment of dose if required.</p>
<p>Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.</p>
<p>Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.12"></a><a name="section-7.12"></a><p></p>
<h2>7.12 	Interactions With Investigations of Neuroendocrine Tumors</h2>
<p class="First">Drug-induced decrease in gastric acidity results in enterochromaffin-like cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> and increased Chromogranin A levels which may interfere with investigations for neuroendocrine tumors [see <span class="Italics"><a href="#S5.22">Warnings and Precautions (5.22)</a> and <a href="#S12.2">Clinical Pharmacology (12.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.13"></a><a name="section-7.13"></a><p></p>
<h2>7.13	Drug/Laboratory Test Interaction</h2>
<p class="First">Naproxen may decrease platelet aggregation and prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>. This effect should be kept in mind when <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding times</span> are determined.</p>
<p>The administration of naproxen may result in increased urinary values for 17-ketogenic steroids because of an interaction between the drug and/or its metabolites with m-di-nitrobenzene used in this assay. Although 17-hydroxy-corticosteroid measurements (Porter-Silber test) do not appear to be artifactually altered, it is suggested that therapy with naproxen be temporarily discontinued 72 hours before adrenal function tests are performed if the Porter-Silber test is to be used.</p>
<p>Naproxen may interfere with some urinary assays of 5-hydroxy indoleacetic acid (5HIAA).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.14"></a><a name="section-7.14"></a><p></p>
<h2>7.14	Interactions Related to Absorption</h2>
<p class="First">Due to its effects on gastric acid secretion, esomeprazole can reduce the absorption of drugs where gastric pH is an important determinant of their bioavailability.  Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole.  Esomeprazole is an enantiomer of omeprazole.</p>
<p>Concomitant treatment with omeprazole (20 mg daily) and digoxin in healthy subjects increased the bioavailability of digoxin by 10% (30% in two subjects).  Co-administration of digoxin with VIMOVO is expected to increase the systemic exposure of digoxin.  Therefore, patients may need to be monitored when digoxin is taken concomitantly with VIMOVO.</p>
<p>Co-administration of omeprazole in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.  The clinical relevance of reduced MPA exposure on organ rejection has not been established in transplant patients receiving VIMOVO and MMF.  Use VIMOVO with caution in transplant patients receiving MMF [see <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.15"></a><a name="section-7.15"></a><p></p>
<h2>7.15	Antiretroviral Agents</h2>
<p class="First">Concomitant use of atazanavir and nelfinavir with proton pump inhibitors such as esomeprazole is not recommended. Co-administration of atazanavir with proton pump inhibitors is expected to substantially decrease atazanavir plasma concentrations and thereby reduce its therapeutic effect.</p>
<p>Omeprazole, the racemate of esomeprazole, has been reported to interact with some antiretroviral drugs. The clinical importance and the mechanisms behind these interactions are not always known. Increased gastric pH during omeprazole treatment may change the absorption of the antiretroviral drug. Other possible interaction mechanisms are via CYP2C19. For some antiretroviral drugs, such as atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole. Following multiple doses of nelfinavir (1250 mg, twice daily) and omeprazole (40 mg once a day), AUC was decreased by 36% and 92%, C<span class="Sub">max</span> by 37% and 89% and C<span class="Sub">min</span> by 39% and 75% respectively for nelfinavir and main oxidative metabolite, hydroxy-<span class="Italics">t</span>-butylamide (M8). Following multiple doses of atazanavir (400 mg, once a day) and omeprazole (40 mg, once a day, 2 hr before atazanavir), AUC was decreased by 94%, C<span class="Sub">max</span> by 96%, and C<span class="Sub">min</span> by 95%. Concomitant administration with omeprazole and drugs such as atazanavir and nelfinavir is therefore not recommended. For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported with an increase in AUC by 82% in C<span class="Sub">max </span>by 75% and in C<span class="Sub">min </span>by 106% following multiple dosing of saquinavir/ritonavir (1000/100 mg) twice a day for 15 days with omeprazole 40 mg once a day co-administered on days 11 to 15. Therefore, clinical and laboratory monitoring for saquinavir toxicity is recommended during concurrent use with esomeprazole. Dose reduction of saquinavir should be considered from the safety perspective for individual patients. There are also some antiretroviral drugs of which unchanged serum levels have been reported when given with omeprazole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.16"></a><a name="section-7.16"></a><p></p>
<h2>7.16	Effects on Hepatic Metabolism/Cytochrome P-450 pathways</h2>
<p class="First">Esomeprazole is extensively metabolized in the liver by CYP2C19 and CYP3A4.</p>
<p><span class="Italics">In vitro</span> and <span class="Italics">in vivo</span> studies have shown that esomeprazole is not likely to inhibit CYPs 1A2, 2A6, 2C9, 2D6, 2E1 and 3A4. No clinically relevant interactions with drugs metabolized by these CYP enzymes would be expected. Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, quinidine, clarithromycin or amoxicillin.</p>
<p>However, post-marketing reports of changes in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> measures have been received among patients on concomitant warfarin and esomeprazole therapy. Increases in INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time may lead to abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time.</p>
<p>Esomeprazole may potentially interfere with CYP2C19, the major esomeprazole metabolizing enzyme. Co-administration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.</p>
<p>Clopidogrel is metabolized to its active metabolite in part by CYP2C19. Concomitant use of esomeprazole 40 mg results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition. Avoid concomitant administration of esomeprazole with clopidogrel. When using esomeprazole, a component of VIMOVO, consider use of alternative anti-platelet therapy [<span class="Italics">see <a href="#S12.3">Pharmacokinetics (12.3)</a></span>].</p>
<p>Concomitant administration of esomeprazole and a combined inhibitor of CYP2C19 and CYP3A4, such as voriconazole, may result in more than doubling of the esomeprazole exposure. Dose adjustment of esomeprazole is not normally required. Omeprazole acts as an inhibitor of CYP2C19. Omeprazole, given in doses of 40 mg daily for one week to 20 healthy subjects in cross-over study, increased C<span class="Sub">max</span> and AUC of cilostazol by 18% and 26% respectively. C<span class="Sub">max</span> and AUC of one of its active metabolites, 3,4-dihydrocilostazol, which has 4-7 times the activity of cilostazol, were increased by 29% and 69% respectively. Co-administration of cilostazol with esomeprazole is expected to increase concentrations of cilostazol and its above mentioned active metabolite. Therefore a dose reduction of cilostazol from 100 mg twice daily to 50 mg twice daily should be considered.</p>
<p>Drugs known to induce CYP2C19 or CYP3A4 (such as rifampin) may lead to decreased esomeprazole serum levels. Omeprazole, of which esomeprazole is an enantiomer, has been reported to interact with St. John's Wort, an inducer of CYP3A4. In a cross-over study in 12 healthy male subjects, St John's Wort (300 mg three times daily for 14 days) significantly decreased the systemic exposure of omeprazole in CYP2C19 poor metabolizers (C<span class="Sub">max</span> and AUC decreased by 37.5% and 37.9%, respectively) and extensive metabolizers (C<span class="Sub">max</span> and AUC decreased by 49.6% and 43.9%, respectively). Avoid concomitant use of St. John's Wort or rifampin with VIMOVO.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.17"></a><a name="section-7.17"></a><p></p>
<h2>7.17	Other Pharmacokinetic-based Interactions</h2>
<p class="First">Co-administration of oral contraceptives, diazepam, phenytoin, or quinidine does not seem to change the pharmacokinetic profile of esomeprazole.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1	Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category C prior to 30 weeks gestation; Category D starting 30 weeks gestation.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.1"></a><p></p>
<p class="First"><span class="Bold Italics">Risk Summary</span></p>
<p>There are no adequate and well-controlled studies with VIMOVO in pregnant women. VIMOVO contains naproxen and esomeprazole magnesium. Esomeprazole is the S-isomer of omeprazole. Available epidemiologic data fail to demonstrate an increased risk of major congenital malformations or other adverse pregnancy outcomes with first trimester omeprazole use. However, starting at 30 weeks gestation VIMOVO, as with other NSAID-containing products, should be avoided because NSAIDs can cause premature closure of the ductus arteriosus. Animal reproduction studies with naproxen conducted in rats and rabbits at 0.23 and 0.27 times the human systemic exposure showed no evidence of impaired fertility or harm to the fetus. <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span> was not observed in animal reproduction studies with esomeprazole magnesium at doses about 68 times and 42 times a human dose of 40 mg (based on a body surface area basis for a 60 kg person) in rats and rabbits, respectively. However, changes in bone morphology and physeal <span class="product-label-link" type="condition" conceptid="4093447" conceptname="Dysplasia">dysplasia</span> were observed in offspring of rats dosed through most of pregnancy and lactation at doses equal to or greater than approximately 33.6 times an oral human dose of 40 mg <span class="Italics">(see <a href="#ad">Animal Data</a>)</span>. Because of the observed effect at high doses of esomeprazole magnesium on developing bone in rat studies, Vimovo should be used prior to 30 weeks gestation only if the potential benefit justifies the potential risk to the fetus. Starting at 30 weeks gestation, if this drug is used, the patient should be apprised of the potential hazard to the fetus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.2"></a><p></p>
<p class="First"><span class="Bold Italics">Clinical Considerations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.2.1"></a><p></p>
<p class="First">Fetal/Neonatal Adverse Reactions</p>
<p>There is some evidence to suggest that when inhibitors of prostaglandin synthesis, such as an NSAID, naproxen, a component of VIMOVO, are used to delay preterm labor there is an increased risk of neonatal complications such as <span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">necrotizing enterocolitis</span>, <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span> and <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>. Naproxen treatment given in late pregnancy to delay parturition has been associated with persistent <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>, renal dysfunction and abnormal prostaglandin E levels in preterm infants.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.2.2"></a><p></p>
<p class="First"><span class="Bold Italics">Labor or Delivery</span></p>
<p>Naproxen-containing products are not recommended in labor and delivery because, through its prostaglandin synthesis inhibitory effect, naproxen may adversely affect fetal circulation and inhibit uterine contractions, thus increasing the risk of <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine hemorrhage</span>. In rat studies with NSAIDs, as with other drugs known to inhibit prostaglandin synthesis, an increased incidence of dystocia, delayed parturition, and decreased pup survival occurred.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.3"></a><p></p>
<p class="First"><span class="Bold Italics">Human Data</span></p>
<p>Esomeprazole is the S-isomer of omeprazole. Four epidemiological studies compared the frequency of congenital abnormalities among infants born to women who used omeprazole during pregnancy with the frequency of abnormalities among infants of women exposed to H<span class="Sub">2</span>-receptor antagonists or other controls.</p>
<p>A population-based retrospective cohort epidemiological study from the Swedish Medical Birth Registry, covering approximately 99% of pregnancies, from 1995-99, reported on 955 infants (824 exposed during the first trimester with 39 of these exposed beyond first trimester, and 131 exposed after the first trimester) whose mothers used omeprazole during pregnancy. The number of infants exposed <span class="Italics">in utero </span>to omeprazole that had any malformation, low birth weight, low Apgar score, or hospitalization was similar to the number observed in this population. The number of infants born with <span class="product-label-link" type="condition" conceptid="434462" conceptname="Ventricular septal defect">ventricular septal defects</span> and the number of stillborn infants was slightly higher in the omeprazole-exposed infants than the expected number in this population. </p>
<p>A population-based retrospective cohort study covering all live births in Denmark from 1996-2009, reported on 1,800 live births whose mothers used omeprazole during the first trimester of pregnancy and 837, 317 live births whose mothers did not use any proton pump inhibitor. The overall rate of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in infants born to mothers with first trimester exposure to omeprazole was 2.9% and 2.6% in infants born to mothers not exposed to any proton pump inhibitor during the first trimester.</p>
<p>A retrospective cohort study reported on 689 pregnant women exposed to either H<span class="Sub">2</span>-blockers or omeprazole in the first trimester (134 exposed to omeprazole) and 1,572 pregnant women unexposed to either during the first trimester. The overall malformation rate in offspring born to mothers with first trimester exposure to omeprazole, an H2-blocker, or were unexposed was 3.6%, 5.5%, and 4.1% respectively.</p>
<p>A small prospective observational cohort study followed 113 women exposed to omeprazole during pregnancy (89% first trimester exposures). The reported rate of major congenital malformations was 4% in the omeprazole group, 2% in controls exposed to non-teratogens, and 2.8% in disease-paired controls. Rates of spontaneous and elective abortions, preterm deliveries, gestational age at delivery, and mean birth weight were similar among the groups.</p>
<p>Several studies have reported no apparent adverse short-term effects on the infant when single dose oral or intravenous omeprazole was administered to over 200 pregnant women as premedication for cesarean section under general anesthesia.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ad"></a><a name="section-8.1.1.4"></a><p></p>
<p class="First"><span class="Bold Italics">Animal Data</span></p>
<p>There are no reproduction studies in animals with VIMOVO. Reproduction studies with naproxen have been performed in rats at 20 mg/kg/day (125 mg/m<span class="Sup">2</span>/day, 0.23 times the human systemic exposure), rabbits at 20 mg/kg/day (220 mg/m<span class="Sup">2</span>/day, 0.27 times the human systemic exposure), and mice at 170 mg/kg/day (510 mg/m<span class="Sup">2</span>/day, 0.28 times the human systemic exposure) with no evidence of impaired fertility or harm to the fetus due to the drug. Reproduction studies have been performed with esomeprazole magnesium in rats at oral doses up to 280 mg/kg/day (about 68 times an oral human dose of 40 mg on a body surface area basis) and in rabbits at oral doses up to 86 mg/kg/day (about 42 times an oral human dose of 40 mg on a body surface area basis) and have revealed no evidence of impaired fertility or harm to the fetus due to esomeprazole magnesium.</p>
<p>A pre- and postnatal developmental toxicity study in rats with additional endpoints to evaluate bone development were performed with esomeprazole magnesium at oral doses of 14 to 280 mg/kg/day (about 3.4 to 68 times a daily human dose of 40 mg on a body surface area basis). Neonatal/early postnatal (birth to weaning) survival was decreased at doses equal to or greater than 138 mg/kg/day (about 33.6 times an oral human dose of 40 mg on a body surface area basis). Body weight and body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> were reduced and neurobehavioral or general <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delays</span> in the immediate post-weaning timeframe were evident at doses equal to or greater than 69 mg /kg/day (about 16.8 times an oral human dose of 40 mg on a body surface area basis). In addition, decreased femur length, width and thickness of cortical bone, decreased thickness of the tibial growth plate and minimal to mild bone marrow hypocellularity were noted at doses equal to or greater than 14 mg/kg/day (about 3.4 times a daily human dose of 40 mg on a body surface area basis). Physeal <span class="product-label-link" type="condition" conceptid="4093447" conceptname="Dysplasia">dysplasia</span> in the femur was observed in offspring of rats treated with oral doses of esomeprazole magnesium at doses equal to or greater than 138 mg/kg/day (about 33.6 times the daily human dose of 40 mg on a body surface area basis).</p>
<p>Effects on maternal bone were observed in pregnant and lactating rats in the pre- and postnatal toxicity study when esomeprazole magnesium was administered at oral doses of 14 to 280 mg /kg/day (about 3.4 to 68 times an oral human dose of 40 mg on a body surface area basis).  When rats were dosed from gestational day 7 through weaning on postnatal day 21, a statistically significant decrease in maternal femur weight of up to 14% (as compared to placebo treatment) was observed at doses equal to or greater than 138 mg/kg/day (about 33.6 times an oral human dose of 40 mg on a body surface area basis).</p>
<p>A pre- and postnatal development study in rats with esomeprazole strontium (using equimolar doses compared to esomeprazole magnesium study) produced similar results in dams and pups as described above.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3	Nursing Mothers</h2>
<p class="First">VIMOVO is likely present in human milk.  The naproxen anion has been found in the milk of lactating women at a concentration equivalent to approximately 1% of maximum naproxen concentration in plasma.  Esomeprazole is the S-isomer of omeprazole and limited data indicate that maternal doses of omeprazole 20 mg daily produce low levels in human milk.  The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for VIMOVO and any potential adverse effects on the breastfed child from the drug or from the underlying maternal condition.  Exercise caution when administering VIMOVO to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4	Pediatric Use</h2>
<p class="First">The safety and efficacy of VIMOVO has not been established in pediatric patients younger than 18 years.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.1"></a><p></p>
<p class="First"><span class="Bold Italics">Juvenile Animal Data</span></p>
<p>In a juvenile rat toxicity study, esomeprazole was administered with both magnesium and strontium salts at oral doses about 34 to 68 times a daily human dose of 40 mg based on body surface area. Increases in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were seen at the high dose, and at all doses of esomeprazole, there were decreases in body weight, body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, femur weight and femur length, and decreases in overall growth<span class="Italics"> [see <a href="#S13.2">Nonclinical Toxicology (13.2)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5	Geriatric Use</h2>
<p class="First">Of the total number of patients who received VIMOVO (n=1157) in clinical trials, 387 were ≥65 years of age, of which 85 patients were 75 years and over. No meaningful differences in efficacy or safety were observed between these subjects and younger subjects [see<span class="Italics"><a href="#S6"> Adverse Reactions (6)</a></span>]<span class="Italics">.</span></p>
<p>Studies indicate that although total plasma concentration of naproxen is unchanged, the unbound plasma fraction of naproxen is increased in the elderly. Caution is advised when high doses are required and some adjustment of dosage may be required in elderly patients. As with other drugs used in the elderly, it is prudent to use the lowest effective dose [see <span class="Italics"><a href="#S2">Dosage and Administration (2)</a></span> and <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span>]<span class="Italics">.</span></p>
<p>Experience indicates that geriatric patients may be particularly sensitive to certain adverse effects of NSAIDs. Elderly or debilitated patients seem to tolerate <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulceration</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> less well when these events do occur. Most spontaneous reports of fatal GI events are in the geriatric population [see<span class="Italics"><a href="#S5.4"> Warnings and Precautions (5.4)</a></span>]<span class="Italics">.</span></p>
<p>Naproxen is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Geriatric patients may be at a greater risk for the development of a form of renal toxicity precipitated by reduced prostaglandin formation during administration of NSAIDs [see<span class="Italics"><a href="#S5.6"> Warnings and Precautions (5.6</a>, <a href="#S5.7">5.7)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6	<span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h2>
<p class="First">VIMOVO should be avoided in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> because naproxen may increase the risk of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and esomeprazole doses should not exceed 20 mg daily in these patients [see <span class="Italics"><a href="#S2">Dosage and Administration (2)</a>, <a href="#S5.11">Warnings and Precautions (5.11</a></span>), and <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7	<span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></h2>
<p class="First">Naproxen-containing products, including VIMOVO, are not recommended for use in patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> [see <span class="Italics"><a href="#S2">Dosage and Administration (2)</a>,</span> and<span class="Italics"><a href="#S5.6"> Warnings and Precautions (5.6</a>, <a href="#S5.7">5.7)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.8"></a><a name="section-8.7"></a><p></p>
<h2>8.8	Females and Males of Reproductive Potential</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.7.1"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Infertility</span></span></p>
<p>Data from several small studies in humans and from studies in animals indicate that NSAIDs, including naproxen, may be associated with a reversible delay in ovulation.  Therefore, in women who have difficulties conceiving, or who are undergoing investigation of <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span>, use of VIMOVO is not recommended.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10	OVERDOSAGE</h1>
<p class="First">There is no clinical data on overdosage with VIMOVO.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<p class="First"><span class="Bold Italics">Overdosage of naproxen:</span></p>
<p>Significant naproxen overdosage may be characterized by <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, transient alterations in liver function, <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>, renal dysfunction, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal bleeding</span> can occur. <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> may occur, but are rare. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> have been reported with therapeutic ingestion of NSAIDs, and may occur following an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. A few patients have experienced <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, but it is not clear whether or not these were drug-related. It is not known what dose of the drug would be life threatening. The oral LD<span class="Sub">50</span> of the drug is 543 mg/kg in rats, 1234 mg/kg in mice, 4110 mg/kg in hamsters, and greater than 1000 mg/kg in dogs.</p>
<p>Patients should be managed by symptomatic and supportive care following an NSAID <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. There are no specific antidotes. Hemodialysis does not decrease the plasma concentration of naproxen because of the high degree of its protein binding. Activated charcoal (60 to 100 g in adults, 1 to 2 g/kg in children) and/or osmotic cathartic may be indicated in patients seen within 4 hours of ingestion with symptoms or following a large <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, alkalinization of urine or hemoperfusion may not be useful due to high protein binding.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<p class="First"><span class="Bold Italics">Overdosage of esomeprazole:</span></p>
<p>A single oral dose of esomeprazole at 510 mg/kg (about 124 times the human dose on a body surface area basis for a 60 kg person) was lethal to rats. The major signs of acute toxicity were reduced motor activity, changes in respiratory frequency, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, and intermittent <span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic convulsions</span>.</p>
<p>The symptoms described in connection with deliberate esomeprazole <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (limited experience of doses in excess of 240 mg/day) are transient. Single doses of 80 mg of esomeprazole were uneventful. Reports of overdosage with omeprazole in humans may also be relevant. Doses ranged up to 2,400 mg (120 times the usual recommended clinical dose). Manifestations were variable, but included <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, and other adverse reactions similar to those seen in normal clinical experience (see omeprazole package insert - <span class="Italics">Adverse Reactions</span>). No specific antidote for esomeprazole is known. Since esomeprazole is extensively protein bound, it is not expected to be removed by dialysis. In the event of overdosage, treatment should be symptomatic and supportive.</p>
<p>If overexposure occurs, call the Poison Control Center at 1-800-222-1222.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11	DESCRIPTION</h1>
<p class="First">The active ingredients of VIMOVO are naproxen which is a NSAID and esomeprazole magnesium which is a Proton Pump Inhibitor (PPI).</p>
<p>VIMOVO is available as an oval, yellow, multi-layer, delayed release tablet combining an enteric coated naproxen core and an immediate release esomeprazole magnesium layer surrounding the core. Each strength contains either 375 mg of naproxen and 20 mg of esomeprazole (present as 22.3 mg esomeprazole magnesium trihydrate) or 500 mg of naproxen and 20 mg of esomeprazole (present as 22.3 mg esomeprazole magnesium trihydrate) for oral administration. The inactive ingredients are carnauba wax, colloidal silicon dioxide, croscarmellose sodium, iron oxide yellow, glyceryl monostearate, hypromellose, iron oxide black, magnesium stearate, methacrylic acid copolymer dispersion, methylparaben, polysorbate 80, polydextrose, polyethylene glycol, povidone, propylene glycol, propylparaben, titanium dioxide, and triethyl citrate.</p>
<p>The chemical name for naproxen is (S)-6-methoxy-α-methyl-2-naphthaleneacetic acid. Naproxen has the following structure:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=baa47781-7151-4c75-a9a2-d2eac0a7d55e&amp;name=vimovo-01.jpg"></p>
<p>Naproxen has a molecular weight of 230.26 and a molecular formula of C<span class="Sub">14</span>H<span class="Sub">14</span>O<span class="Sub">3</span>.</p>
<p>Naproxen is an odorless, white to off-white crystalline substance. It is lipid soluble, practically insoluble in water at low pH and freely soluble in water at high pH. The octanol/water partition coefficient of naproxen at pH 7.4 is 1.6 to 1.8.</p>
<p>The chemical name for esomeprazole is bis(5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1<span class="Italics">H</span>-benzimidazole-1-yl) magnesium trihydrate. Esomeprazole is the S-isomer of omeprazole, which is a mixture of the S- and R- isomers. Its molecular formula is (C<span class="Sub">17</span>H<span class="Sub">18</span>N<span class="Sub">3</span>O<span class="Sub">3</span>S)<span class="Sub">2</span>Mg × 3 H<span class="Sub">2</span>O with molecular weight of 767.2 as a trihydrate and 713.1 on an anhydrous basis. The structural formula is:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=baa47781-7151-4c75-a9a2-d2eac0a7d55e&amp;name=vimovo-02.jpg"></p>
<p>The magnesium salt is a white to slightly colored crystalline powder. It contains 3 moles of water of solvation and is slightly soluble in water.</p>
<p>The stability of esomeprazole magnesium is a function of pH; it rapidly degrades in acidic media, but it has acceptable stability under alkaline conditions. At pH 6.8 (buffer), the half-life of the magnesium salt is about 19 hours at 25°C and about 8 hours at 37°C.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12	CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<p class="First">VIMOVO consists of an immediate-release esomeprazole magnesium layer and an enteric-coated naproxen core. As a result, esomeprazole is released first in the stomach, prior to the dissolution of naproxen in the small intestine. The enteric coating prevents naproxen release at pH levels below 5.5.</p>
<p>Naproxen is a NSAID with analgesic and antipyretic properties. The mechanism of action of the naproxen anion, like that of other NSAIDs, is not completely understood but may be related to prostaglandin synthetase inhibition.</p>
<p>Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H<span class="Sup">+</span>/K<span class="Sup">+</span>-ATPase in the gastric parietal cell. Esomeprazole is protonated and converted in the acidic compartment of the parietal cell forming the active inhibitor, the achiral sulphenamide. By acting specifically on the proton pump, esomeprazole blocks the final step in acid production, thus reducing gastric acidity. This effect is dose-related up to a daily dose of 20 to 40 mg and leads to inhibition of gastric acid secretion.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2	Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Bold Italics">Antisecretory Activity</span></p>
<p>The effect of VIMOVO on intragastric pH was determined in 25 healthy volunteers in one study. Three VIMOVO combinations (naproxen 500 mg combined with either esomeprazole 10, 20, or 30 mg) were administered twice daily over 9 days. The results are shown in the following table:</p>
<a name="table3"></a><table width="75%">
<caption><span>Table 3:  Effect on Intragastric pH on Day 9 (N=25)</span></caption>
<col align="left" valign="top" width="34%">
<col align="left" valign="top" width="22%">
<col align="left" valign="top" width="22%">
<col align="left" valign="top" width="22%">
<thead>
<tr class="Botrule First">
<th align="left"></th>
<th align="left" colspan="3">Naproxen 500 mg combined with esomeprazole</th>
</tr>
<tr class="Botrule Last">
<th align="left"></th>
<th align="left">10 mg</th>
<th align="left">20 mg</th>
<th align="left">30 mg</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="4">LS Mean (SE)</td></tr>
<tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Gastric pH was measured over a 24-hour period</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left">% Time Gastric<br>pH &gt;4<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>
</td>
<td align="left">41.1 (3.0)</td>
<td align="left">71.5 (3.0)</td>
<td align="left">76.8 (3.0)</td>
</tr>
<tr class="Last">
<td align="left">Coefficient of variation</td>
<td align="left">55%</td>
<td align="left">18%</td>
<td align="left">16%</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1.1"></a><p></p>
<p class="First"><span class="Bold Italics">Serum Gastrin Effects</span></p>
<p>The effect of esomeprazole on serum gastrin concentrations was evaluated in approximately 2,700 patients in clinical trials up to 8 weeks and in over 1,300 patients for up to 6-12 months. The mean fasting gastrin level increased in a dose-related manner. This increase reached a plateau within two to three months of therapy and returned to baseline levels within four weeks after discontinuation of therapy.</p>
<p>Increased gastrin causes enterochromaffin-like cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> and increased serum Chromogranin A (CgA) levels. The increased CgA levels may cause false positive results in diagnostic investigations for neuroendocrine tumors. Healthcare providers should temporarily stop esomeprazole treatment at least 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1.2"></a><p></p>
<p class="First"><span class="Bold Italics">Enterochromaffin-like (ECL) Cell Effects</span></p>
<p>In over 1,000 patients treated with esomeprazole (10, 20 or 40 mg/day) up to 6-12 months, the prevalence of ECL cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> increased with time and dose. No patient developed ECL cell carcinoids, <span class="product-label-link" type="condition" conceptid="4093447" conceptname="Dysplasia">dysplasia</span>, or neoplasia in the gastric mucosa.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1.3"></a><p></p>
<p class="First"><span class="Bold Italics">Endocrine Effects</span></p>
<p>Esomeprazole had no effect on thyroid function when given in oral doses of 20 or 40 mg for 4 weeks. Other effects of esomeprazole on the endocrine system were assessed using omeprazole studies. Omeprazole given in oral doses of 30 or 40 mg for 2 to 4 weeks had no effect on carbohydrate metabolism, circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1.4"></a><p></p>
<p class="First"><span class="Bold Italics">Effects on Gastrointestinal Microbial Ecology</span></p>
<p>Decreased gastric acidity due to any means including proton pump inhibitors, increases gastric counts of bacteria normally present in the gastrointestinal tract. Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> such as <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span> and <span class="Italics">Campylobacter</span> and, in hospitalized patients, possibly also <span class="Italics">Clostridium difficile</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3	Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Bold Italics">Absorption</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1.1"></a><p></p>
<p class="First"><span class="Underline">Naproxen</span></p>
<p>At steady state following administration of VIMOVO twice daily, peak plasma concentrations of naproxen are reached on average 3 hours following both the morning and the evening dose.</p>
<p>Bioequivalence between VIMOVO and enteric-coated naproxen, based on both area under the plasma concentration-time curve (AUC) and maximum plasma concentration (C<span class="Sub">max</span>) of naproxen, has been demonstrated for both the 375 mg and 500 mg doses.</p>
<p>Naproxen is absorbed from the gastrointestinal tract with an <span class="Italics">in vivo</span> bioavailability of 95%.</p>
<p>Steady-state levels of naproxen are reached in 4 to 5 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1.2"></a><p></p>
<p class="First"><span class="Underline">Esomeprazole</span></p>
<p>Following administration of VIMOVO twice daily, esomeprazole is rapidly absorbed with peak plasma concentration reached within on average, 0.43 to 1.2 hours, following the morning and evening dose on both the first day of administration and at steady state. The peak plasma concentrations of esomeprazole are higher at steady state compared to on first day of dosing of VIMOVO.</p>
<p>Figure 1 represents the pharmacokinetics of naproxen and esomeprazole following administration of VIMOVO 500 mg/20 mg.</p>
<p><span class="Bold">Figure 1:  Mean plasma concentrations of naproxen and esomeprazole following single dose administration of VIMOVO (500mg/20 mg)</span></p>
<p><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=baa47781-7151-4c75-a9a2-d2eac0a7d55e&amp;name=vimovo-03.jpg"></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Bold Italics">Food effect</span></p>
<p>Administration of VIMOVO together with high-fat food in healthy volunteers does not affect the extent of absorption of naproxen but significantly prolongs t<span class="Sub">max</span> by 10 hours and decreases peak plasma concentration (C<span class="Sub">max</span>) by about 12%.</p>
<p>Administration of VIMOVO together with high-fat food in healthy volunteers delays t<span class="Sub">max</span> of esomeprazole by 1 hour  and significantly reduces the extent of absorption, resulting in 52% and 75% reductions of area under the plasma concentration versus time curve (AUC) and peak plasma concentration (C<span class="Sub">max</span>), respectively.</p>
<p>Administration of VIMOVO 30 minutes before high-fat food intake in healthy volunteers does not affect the extent of absorption of naproxen but delays the absorption by about 4 hours and decreases peak plasma concentration (C<span class="Sub">max</span>) by about 17%, but has no significant effect on the rate or extent of esomeprazole absorption compared to administration under fasted conditions [see<span class="Italics"><a href="#S2"> Dosage and Administration (2)</a></span>].</p>
<p>Administration of VIMOVO 60 minutes before high-fat food intake in healthy volunteers has no effect on the rate and extent of naproxen absorption; however, increases the esomeprazole AUC by 25% and C<span class="Sub">max</span> by 50% compared to administration under fasted conditions. This increase in esomeprazole C<span class="Sub">max</span> does not raise a safety issue since the approved dosing regimen of esomeprazole at 40 mg QD would result in higher C<span class="Sub">max</span> [see <span class="Italics"><a href="#S2">Dosage and Administration (2)</a></span>].</p>
<p>Therefore, VIMOVO should be taken at least 30 minutes before the meal.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Bold Italics">Distribution</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3.1"></a><p></p>
<p class="First"><span class="Underline">Naproxen</span></p>
<p>Naproxen has a volume of distribution of 0.16 L/kg. At therapeutic levels naproxen is greater than 99% albumin-bound. At doses of naproxen greater than 500 mg/day there is less than proportional increase in plasma levels due to an increase in clearance caused by saturation of plasma protein binding at higher doses (average trough C<span class="Sub">ss</span> 36.5, 49.2 and 56.4 mg/L with 500, 1000 and 1500 mg daily doses of naproxen, respectively). The naproxen anion has been found in the milk of lactating women at a concentration equivalent to approximately 1% of maximum naproxen concentration in plasma [see <span class="Italics"><a href="#S8.3">Use in Specific Populations (8.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3.2"></a><p></p>
<p class="First"><span class="Underline">Esomeprazole</span></p>
<p>The apparent volume of distribution at steady state in healthy subjects is approximately 16L. Esomeprazole is 97% plasma protein bound.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Bold Italics">Metabolism</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4.1"></a><p></p>
<p class="First"><span class="Underline">Naproxen</span></p>
<p>Naproxen is extensively metabolized in the liver by the cytochrome P450 system (CYP), CYP2C9 and CYP1A2, to 6-0-desmethyl naproxen. Neither the parent drug nor the metabolites induce metabolizing enzymes. Both naproxen and 6-0-desmethyl naproxen are further metabolized to their respective acylglucuronide conjugated metabolites. Consistent with the half-life of naproxen, the area under the plasma concentration time curve increases with repeated dosing of VIMOVO twice daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4.2"></a><p></p>
<p class="First"><span class="Underline">Esomeprazole</span></p>
<p>Esomeprazole is extensively metabolized in the liver by the CYP enzyme system. The major part of the metabolism of esomeprazole is dependent on the polymorphic CYP2C19, responsible for the formation of the hydroxyl- and desmethyl metabolites of esomeprazole. The remaining part is dependent on another specific isoform CYP3A4, responsible for the formation of esomeprazole sulphone, the main metabolite in plasma. The major metabolites of esomeprazole have no effect on gastric acid secretion.</p>
<p>The area under the plasma esomeprazole concentration-time curve increases with repeated administration of VIMOVO. This increase is dose-dependent and results in a non-linear dose-AUC relationship after repeated administration. An increased absorption of esomeprazole with repeated administration of VIMOVO probably also contributes to the time-and dose-dependency.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Bold Italics">Excretion</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.1"></a><p></p>
<p class="First"><span class="Underline">Naproxen</span></p>
<p>Following administration of VIMOVO twice daily, the mean elimination half-life for naproxen is approximately 15 hours following the evening dose, with no change with repeated dosing.</p>
<p>The clearance of naproxen is 0.13 mL/min/kg. Approximately 95% of the naproxen from any dose is excreted in the urine, primarily as naproxen (&lt;1%), 6-0-desmethyl naproxen (&lt;1%) or their conjugates (66% to 92%). Small amounts, 3% or less of the administered dose, are excreted in the feces. In patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, metabolites may accumulate [see <span class="Italics"><a href="#S5.6">Warnings and Precautions (5.6</a>, <a href="#S5.7">5.7)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.2"></a><p></p>
<p class="First"><span class="Underline">Esomeprazole</span></p>
<p>Following administration of VIMOVO twice daily, the mean elimination half-life of esomeprazole is approximately 1 hour following both the morning and evening dose on day 1, with a slightly longer elimination half-life at steady state (1.2-1.5 hours).</p>
<p>Almost 80% of an oral dose of esomeprazole is excreted as metabolites in the urine, the remainder in the feces. Less than 1% of the parent drug is found in the urine.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6"></a><p></p>
<p class="First"><span class="Bold Italics">Concomitant Use with Clopidogrel</span></p>
<p>Results from a crossover study in healthy subjects have shown a <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> between clopidogrel (300 mg loading dose/75 mg daily maintenance dose) and esomeprazole (40 mg p.o. once daily) when co-administered for 30 days. Exposure to the active metabolite of clopidogrel was reduced by 35% to 40% over this time period. Pharmacodynamic parameters were also measured and demonstrated that the change in inhibition of platelet aggregation was related to the change in the exposure to clopidogrel active metabolite.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7"></a><p></p>
<p class="First"><span class="Bold Italics">Concomitant Use with Mycophenolate Mofetil</span></p>
<p>Administration of omeprazole 20 mg twice daily for 4 days and a single 1000 mg dose of MMF approximately one hour after the last dose of omeprazole to 12 healthy subjects in a cross-over study resulted in a 52% reduction in the Cmax and 23% reduction in the AUC of MPA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.8"></a><p></p>
<p class="First"><span class="Bold Italics">Special Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.8.1"></a><p></p>
<p class="First"><span class="Underline">Geriatric Patients</span></p>
<p>There is no specific data on the pharmacokinetics of VIMOVO in patients over age 65.</p>
<p>Studies indicate that although total plasma concentration of naproxen is unchanged, the unbound plasma fraction of naproxen is increased in the elderly, although the unbound fraction is &lt;1% of the total naproxen concentration. Unbound trough naproxen concentrations in elderly subjects have been reported to range from 0.12% to 0.19% of total naproxen concentration, compared with 0.05% to 0.075% in younger subjects. The clinical significance of this finding is unclear, although it is possible that the increase in free naproxen concentration could be associated with an increase in the rate of adverse events per a given dosage in some elderly patients [see <span class="Italics"><a href="#S6">Adverse Reactions (6)</a></span> and <span class="Italics"><a href="#S8.5">Use in Specific Populations (8.5)</a></span>].</p>
<p>The AUC and C<span class="Sub">max</span> values of esomeprazole were slightly higher (25% and 18%, respectively) in the elderly as compared to younger subjects at steady state. Dosage adjustment for the esomeprazole component based on age is not necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.8.2"></a><p></p>
<p class="First"><span class="Underline">Race</span></p>
<p>Pharmacokinetic differences due to race have not been studied for naproxen.</p>
<p>Approximately 3% of Caucasians and 15 to 20% of Asians lack a functional CYP2C19 enzyme and are called poor metabolizers. In these individuals the metabolism of esomeprazole is probably mainly catalyzed by CYP3A4. After repeated once-daily administration of 40 mg esomeprazole, the mean area under the plasma concentration-time curve was approximately 100% higher in poor metabolizers than in subjects having a functional CYP2C19 enzyme (extensive metabolizers).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.8.3"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></span></p>
<p>The pharmacokinetics of VIMOVO or naproxen have not been determined in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p>In patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, VIMOVO should be avoided due to increase of risk of NSAID associated <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and/or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> associated with naproxen.</p>
<p>Chronic <span class="product-label-link" type="condition" conceptid="201612" conceptname="Alcoholic liver damage">alcoholic liver disease</span> and probably also other forms of cirrhosis reduce the total plasma concentration of naproxen, but the plasma concentration of unbound naproxen is increased. The implication of this finding for the naproxen component of VIMOVO dosing is unknown but it is prudent to use the lowest effective dose.</p>
<p>The AUCs of esomeprazole in patients with severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> (Child Pugh Class C) have been shown to be 2-3 times higher than in patients with normal liver function. For this reason, it has been recommended that esomeprazole doses not exceed 20 mg daily in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. However, there is no dose adjustment necessary for patients with Child Pugh Class A and B for the esomeprazole component of VIMOVO. There is no VIMOVO dosage form that contains less than 20 mg esomeprazole for twice daily dosing [see <span class="Italics"><a href="#S2">Dosage and Administration (2)</a>, <a href="#S5.11">Warnings and Precautions (5.11)</a></span>, and <span class="Italics"><a href="#S8.6">Use in Specific Populations (8.6)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.8.4"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></span></p>
<p>The pharmacokinetics of VIMOVO or naproxen have not been determined in subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p>Given that naproxen, its metabolites and conjugates are primarily excreted by the kidney, the potential exists for naproxen metabolites to accumulate in the presence of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. Elimination of naproxen is decreased in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Naproxen-containing products, including VIMOVO, is not recommended for use in patients with moderate to severe and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance &lt;30 ml/min) [see <span class="Italics"><a href="#S2">Dosage and Administration (2)</a>, <a href="#S5.6">Warnings and Precautions (5.6</a></span>, <span class="Italics"><a href="#S5.7">5.7)</a></span>, and <span class="Italics"><a href="#S8.7">Use in Specific Populations (8.7)</a></span>].</p>
<p>No studies have been performed with esomeprazole in patients with decreased renal function. Since the kidney is responsible for the excretion of the metabolites of esomeprazole but not for the elimination of the parent compound, the metabolism of esomeprazole is not expected to be changed in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.8.5"></a><p></p>
<p class="First"><span class="Underline">Gender</span></p>
<p>The AUC and C<span class="Sub">max</span> values of esomeprazole were slightly higher (13%) in females than in males at steady state. Dosage adjustment for the esomeprazole component based on gender is not necessary.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13	NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.1"></a><p></p>
<p class="First"><span class="Bold Italics">Naproxen</span></p>
<p>A 2-year study was performed in rats to evaluate the carcinogenic potential of naproxen at rat doses of 8, 16, and 24 mg/kg/day (50, 100, and 150 mg/m<span class="Sup">2</span>). The maximum dose used was 0.28 times the highest recommended human dose. No evidence of tumorigenicity was found.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.2"></a><p></p>
<p class="First"><span class="Bold Italics">Esomeprazole</span></p>
<p>The carcinogenic potential of esomeprazole was assessed using omeprazole studies, of which esomeprazole is an enantiomer. In two 24-month oral carcinogenicity studies in rats, omeprazole at daily doses of 1.7, 3.4, 13.8, 44 and 140.8 mg/kg/day (about 0.41 to 34.2 times the human dose of 40 mg/day expressed on a body surface area basis) produced gastric ECL cell carcinoids in a dose-related manner in both male and female rats; the incidence of this effect was markedly higher in female rats, which had higher blood levels of omeprazole. Gastric carcinoids seldom occur in the untreated rat. In addition, ECL cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> was present in all treated groups of both sexes. In one of these studies, female rats were treated with 13.8 mg omeprazole/kg/day (about 3.36 times the human dose of 40 mg/day on a body surface area basis) for 1 year, then followed for an additional year without the drug. No carcinoids were seen in these rats. An increased incidence of treatment-related ECL cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> was observed at the end of 1 year (94% treated vs 10% controls). By the second year the difference between treated and control rats was much smaller (46% vs 26%) but still showed more <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> in the treated group. Gastric adenocarcinoma was seen in one rat (2%). No similar tumor was seen in male or female rats treated for 2 years. For this <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of rat no similar tumor has been noted historically, but a finding involving only one tumor is difficult to interpret. A 78-week mouse carcinogenicity study of omeprazole did not show increased tumor occurrence, but the study was not conclusive.</p>
<p>Esomeprazole was negative in the Ames mutation test, in the <span class="Italics">in vivo</span> rat bone marrow cell chromosome aberration test, and the <span class="Italics">in vivo</span> mouse micronucleus test. Esomeprazole, however, was positive in the <span class="Italics">in vitro</span> human lymphocyte chromosome aberration test. Omeprazole was positive in the <span class="Italics">in vitro </span>human lymphocyte chromosome aberration test, the <span class="Italics">in vivo</span> mouse bone marrow cell chromosome aberration test, and the <span class="Italics">in vivo</span> mouse micronucleus test.</p>
<p>The potential effects of esomeprazole on fertility and reproductive performance were assessed using omeprazole studies. Omeprazole at oral doses up to 138 mg/kg/day in rats (about 33.6 times the human dose of 40 mg/day on a body surface area basis) was found to have no effect on reproductive performance of parental animals.</p>
</div>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="S13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2	Animal Toxicology and/or Pharmacology</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.1"></a><p></p>
<p class="First"><span class="Bold Italics">Naproxen</span></p>
<p>Reproduction studies have been performed in rats at 20 mg/kg/day (125 mg/m<span class="Sup">2</span>/day, 0.23 times the maximum recommended human dose), rabbits at 20 mg/kg/day (220 mg/m<span class="Sup">2</span>/day, 0.27 times the maximum recommended human dose), and mice at 170 mg/kg/day (510 mg/m<span class="Sup">2</span>/day, 0.28 times the maximum recommended human dose) with no evidence of impaired fertility or harm to the fetus due to the drug. However, animal reproduction studies are not always predictive of human response.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.2"></a><p></p>
<p class="First"><span class="Bold Italics">Esomeprazole – Reproduction Studies</span></p>
<p>Reproduction studies have been performed in rats at oral doses up to 280 mg/kg/day (about 68 times an oral human dose of 40 mg on a body surface area basis) and in rabbits at oral doses up to 86 mg/kg/day (about 42 times an oral human dose of 40 mg on a body surface area basis) and have revealed no evidence of impaired fertility or harm to the fetus due to esomeprazole [see <span class="Italics"><a href="#S8.1">Pregnancy (8.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.3"></a><p></p>
<p class="First"><span class="Bold Italics">Esomeprazole – Juvenile Animal Data</span></p>
<p>A 28-day toxicity study with a 14-day recovery phase was conducted in juvenile rats with esomeprazole magnesium at doses of 70 to 280 mg /kg/day (about 17 to 68 times a daily oral human dose of 40 mg on a body surface area basis). An increase in the number of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> at the high dose of 280 mg /kg/day was observed when juvenile rats were administered esomeprazole magnesium from postnatal day 7 through postnatal day 35. In addition, doses equal to or greater than 140 mg/kg/day (about 34 times a daily oral human dose of 40 mg on a body surface area basis for a 60 kg person), produced treatment-related decreases in body weight (approximately 14%) and body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, decreases in femur weight and femur length, and affected overall growth. Comparable findings described above have also been observed in this study with another esomeprazole salt, esomeprazole strontium, at equimolar doses of esomeprazole.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 	CLINICAL STUDIES</h1>
<p class="First">Two randomized, multi-center, double-blind trials (Study 1 and Study 2) compared the incidence of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span> formation in 428 patients taking VIMOVO and 426 patients taking enteric-coated naproxen. Subjects were at least 18 years of age with a medical condition expected to require daily NSAID therapy for at least 6 months, and, if less than 50 years old, with a documented history of gastric or <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> within the past 5 years. The majority of patients were female (67%), white (86%). The majority of patients were 50-69 years of age (83%). Approximately one quarter were on low-dose aspirin.</p>
<p>Studies 1 and 2 showed that VIMOVO given as 500 mg/20 mg twice daily statistically significantly reduced the 6-month cumulative incidence of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span> compared to enteric-coated naproxen 500 mg twice daily (see <a href="#table4">Table 4</a>).</p>
<p>Approximately a quarter of the patients in Studies 1 and 2 were taking concurrent low-dose aspirin (≤ 325 mg daily). The results for this subgroup analysis in patients who used aspirin were consistent with the overall findings of the study.</p>
<p>The results at one month, three months, and six months are presented in Table 4.</p>
<a name="table4"></a><table width="75%">
<caption><span>Table 4 – Cumulative Observed Incidence of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcers</span> at 1, 3 and 6 Months</span></caption>
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="2" valign="bottom">Study 1</th>
<th class="Rrule" align="center" colspan="2" valign="bottom">Study 2</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" valign="bottom">VIMOVO<br> N=218<br>number (%)</th>
<th class="Rrule" align="center" valign="bottom">EC-naproxen<br> N=216<br>number (%)</th>
<th class="Rrule" align="center" valign="bottom">VIMOVO<br> N=210<br>number (%)</th>
<th class="Rrule" align="center" valign="bottom">EC-naproxen<br> N=210<br>number (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>For both Studies, p &lt; 0.001 for treatment comparisons of cumulative GU incidence at six months.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="Bold">0-1 Month</span></td>
<td class="Rrule" align="center">3 (1.4)</td>
<td class="Rrule" align="center">28 (13.0)</td>
<td class="Rrule" align="center">4 (1.9)</td>
<td class="Rrule" align="center">21 (10.0)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">0-3 Months</span></td>
<td class="Rrule" align="center">4 (1.8)</td>
<td class="Rrule" align="center">42 (19.4)</td>
<td class="Rrule" align="center">10 (4.8)</td>
<td class="Rrule" align="center">37 (17.6)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">
<span class="Bold">0-6 Months</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="center">9 (4.1)</td>
<td class="Rrule" align="center">50 (23.1)</td>
<td class="Rrule" align="center">15 (7.1)</td>
<td class="Rrule" align="center">51 (24.3)</td>
</tr>
</tbody>
</table>
<p>In these trials, patients receiving VIMOVO had a mean duration of therapy of 152 days compared to 124 days in patients receiving enteric-coated naproxen alone. A higher proportion of patients taking EC-naproxen (12%) discontinued the study due to upper GI adverse events (including <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span>) compared to VIMOVO (4%) in both trials [see <span class="Italics"><a href="#S6">Adverse Reactions (6)</a></span>].</p>
<p>The efficacy of VIMOVO in treating the signs and symptoms of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> was established in two 12-week randomized, double-blind, placebo-controlled trials in patients with <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> (OA) of the knee. In these two trials, patients were allowed to remain on low-dose aspirin for cardioprophylaxis. VIMOVO was given as 500 mg/20 mg twice daily. In each trial, patients receiving VIMOVO had significantly better results compared to patients receiving placebo as measured by change from baseline of the WOMAC <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> subscale and the WOMAC physical function subscale and a Patient Global Assessment Score.</p>
<p>Based on studies with enteric-coated naproxen, improvement in patients treated for <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> was demonstrated by a reduction in <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>, a reduction in duration of morning <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span>, a reduction in disease activity as assessed by both the investigator and patient, and by increased mobility as demonstrated by a reduction in walking time. In patients with <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>, the therapeutic action of naproxen has been shown by a reduction in <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span> or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, an increase in range of motion in knee joints, increased mobility as demonstrated by a reduction in walking time, and improvement in capacity to perform activities of daily living impaired by the disease. In patients with <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">ankylosing spondylitis</span>, naproxen has been shown to decrease night <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, morning <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at rest.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">VIMOVO 375 mg/20 mg tablets are oval, yellow film-coated tablets printed with 375/20 in black ink, supplied as:</p>
<table class="Noautorules" width="40%">
<col align="left" valign="top" width="50%">
<col align="right" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="left">NDC 75987-031-04</td>
<td align="right">Bottles of 60 tablets</td>
</tr></tbody>
</table>
<p>VIMOVO 500 mg/20 mg tablets are oval, yellow film-coated tablets printed with 500/20 in black ink, supplied as:</p>
<table class="Noautorules" width="40%">
<col align="left" valign="top" width="50%">
<col align="right" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="left">NDC 75987-030-04</td>
<td align="right">Bottles of 60 tablets</td>
</tr></tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">Storage</span>:  Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Store in the original container and keep the bottle tightly closed to protect from moisture. Dispense in a tight container if package is subdivided.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17	PATIENT COUNSELING INFORMATION</h1>
<p class="First">"<a href="#MG">See FDA-Approved Medication Guide</a>"</p>
<p>Patients should be informed of the following before initiating therapy with VIMOVO and periodically during the course of ongoing therapy. Patients should also be encouraged to read the NSAID Medication Guide that accompanies each prescription dispensed.</p>
<p>1. VIMOVO, like other NSAID-containing products, may cause serious cardiovascular side effects, such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious cardiovascular events can occur without warning symptoms, patients should be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, slurring of speech, and should ask for medical advice when observing any indicative sign or symptoms. Patients should be apprised of the importance of this follow-up [see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a></span>].</p>
<p>2. VIMOVO has been developed with esomeprazole to decrease incidence of ulceration from naproxen. NSAIDs, including naproxen, can cause GI <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> and, rarely, serious GI side effects, such as <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and should ask for medical advice when observing any indicative sign or symptoms including <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, and <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>. Patients should be apprised of the importance of this follow-up [see <span class="Italics"><a href="#S5.4">Warnings and Precautions (5.4)</a></span>].</p>
<p>3. VIMOVO, like other NSAID-containing products, can cause serious skin side effects such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, which may result in hospitalizations and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> may occur without warning, patients should be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> and <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or other signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> such as <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and should ask for medical advice when observing any indicative signs or symptoms. Patients should be advised to stop the drug immediately if they develop any type of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and contact their physicians as soon as possible [see <span class="Italics"><a href="#S5.9">Warnings and Precautions (5.9)</a></span>].</p>
<p>4. Patients should promptly report signs or symptoms of unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> to their physicians.</p>
<p>5. Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, and "flu-like" symptoms). If these occur, patients should be instructed to stop therapy and seek immediate medical therapy [see <span class="Italics"><a href="#S4">Contraindications (4)</a></span> and <span class="Italics"><a href="#S5.11">Warnings and Precautions (5.11)</a></span>].</p>
<p>6. Patients should be informed of the signs of an <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat). If these occur, patients should be instructed to seek immediate emergency help [see <span class="Italics"><a href="#S5.8">Warnings and Precautions (5.8)</a></span>].</p>
<p>7. Starting at 30 weeks gestation, VIMOVO, as with other NSAIDs, should be avoided because it may cause premature closure of the ductus arteriosus [see <span class="Italics"><a href="#S5.10">Warnings and Precautions (5.10)</a></span> and<span class="Italics"><a href="#S8.1"> Use in Specific Populations (8.1)</a></span>].</p>
<p>8. Caution should be exercised by patients whose activities require alertness if they experience <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> during therapy with VIMOVO.</p>
<p>9. Patients should be instructed to tell their physicians if they have a history of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> because the use of NSAIDs in patients with aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has been associated with severe <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, which can be fatal. Patients with this form of aspirin sensitivity should be instructed not to take VIMOVO. Patients with preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> should be instructed to seek immediate medical attention if their <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> worsens after taking VIMOVO [see <span class="Italics"><a href="#S5.8">Warnings and Precautions (5.8</a>, <a href="#S5.13">5.13)</a></span>].</p>
<p>10. Antacids may be used while taking VIMOVO.</p>
<p>11. VIMOVO tablets should be swallowed whole with liquid. Tablets should not be split, chewed, crushed or dissolved. VIMOVO tablets should be taken at least 30 minutes before meals [see <span class="Italics"><a href="#S2">Dosage and Administration (2)</a></span>].</p>
<p>12. Advise patients to immediately report and seek care for <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> that does not improve. This may be a sign of <span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> [see <span class="Italics"><a href="#S5.18">Warnings and Precautions (5.18)</a></span>].</p>
<p>13. Advise patients to immediately report and seek care for any cardiovascular or neurological symptoms including <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span> as these may be signs of <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> [see <span class="Italics"><a href="#S5.23">Warnings and Precautions (5.23)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">VIMOVO is a trademark of the AstraZeneca group of companies.<br>The VIMOVO trademark has been licensed to Horizon Pharma for use in the US.<br>Other trademarks are the property of AstraZeneca respective companies.</p>
<p>Distributed by:  Horizon Pharma USA, Inc., Deerfield, IL 60015</p>
<p>Rev. 6/2015</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="MG"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">MEDICATION GUIDE<br>VIMOVO<span class="Sup">®</span> (vi-moh-voh)</span><br><span class="Bold">(naproxen and esomeprazole magnesium)</span><br><span class="Bold">delayed release tablets</span></p>
<p>Read this Medication Guide before you start taking VIMOVO and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.</p>
<p><a name="mostimportant"></a><span class="Bold">What is the most important information I should know about VIMOVO?</span></p>
<p><span class="Bold">VIMOVO, which contains naproxen [a nonsteroidal anti-inflammatory drug (NSAID)] and esomeprazole magnesium, may increase the chance of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span> This chance increases:</p>
<ul>
<li>with longer use of NSAID medicines</li>
<li>in people who have heart disease</li>
</ul>
<p><span class="Bold">NSAID-containing medicines, such as VIMOVO, should never be used right before or after a heart surgery called a coronary artery bypass graft (CABG). </span></p>
<p><span class="Bold">NSAID-containing medicines, such as VIMOVO, can cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the stomach and intestines at any time during treatment. <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>: </span></p>
<ul class="Disc">
<li>can happen without warning symptoms</li>
<li>may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></li>
</ul>
<p><span class="Bold">The chance of a person getting an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> increases with: </span></p>
<ul class="Disc">
<li>taking medicines called steroid hormones (corticosteroids) and blood thinners (anticoagulants)</li>
<li>longer use</li>
<li>smoking</li>
<li>drinking alcohol</li>
<li>older age</li>
<li>having poor health</li>
</ul>
<p><span class="Bold">NSAID medicines should only be used: </span></p>
<ul class="Disc">
<li>exactly as prescribed</li>
<li>at the lowest dose possible for your treatment</li>
<li>for the shortest time needed</li>
</ul>
<p><span class="Bold">What are Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)? </span></p>
<p>NSAID medicines are used to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and heat (<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>) from medical conditions such as:</p>
<ul class="Disc">
<li>different types of <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span></li>
<li><span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">menstrual cramps</span> and other types of short-term <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
</ul>
<p><span class="Bold">Who should not take a Non–Steroidal Anti–Inflammatory Drug (NSAID)?</span></p>
<p><span class="Bold">Do not take an NSAID medicine:</span></p>
<ul class="Disc">
<li>if you had an <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, or other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> with aspirin or any other NSAID medicine</li>
<li>for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> right before or after heart bypass surgery</li>
</ul>
<p><span class="Bold">Tell your healthcare provider:</span></p>
<ul class="Disc">
<li>about all of your medical conditions</li>
<li>about all of the medicines you take. NSAIDs and some other medicines can interact with each other and cause serious side effects. <span class="Bold">Keep a list of your medicines to show to your healthcare provider and pharmacist.</span>
</li>
<li>if you are pregnant. <span class="Bold">NSAID medicines should not be used past 30 weeks of pregnancy.</span>
</li>
<li>if you are breastfeeding<span class="Bold">. Talk to your healthcare provider.</span>
</li>
</ul>
<p><span class="Bold">What are the possible side effects of Non–Steroidal Anti–Inflammatory Drugs (NSAIDs)?</span></p>
<table width="75%">
<col align="left" valign="top" width="60%">
<col align="left" valign="top" width="40%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="Bold">Serious side effects include:</span></td>
<td class="Rrule" align="left"><span class="Bold">Other side effects include:</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> </td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">high blood pressure</td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> from body <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>)</td>
<td class="Rrule" align="left">gas</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">kidney problems including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestine</td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">low red blood cells (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>)</td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">life-threatening <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">liver problems including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span></td>
<td class="Rrule" align="left"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks in people who have <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></td>
<td class="Rrule" align="left"></td>
</tr>
</tbody>
</table>
<table class="Noautorules" width="100%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless">
<tr><td align="left" colspan="2"><span class="Bold">Get emergency help right away if you have any of the following symptoms:</span></td></tr>
<tr>
<td align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing</li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in one part or side of your body</li>
</ul></td>
<td align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat</li>
</ul></td>
</tr>
</tbody>
</table>
<table class="Noautorules" width="100%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless">
<tr><td align="left" colspan="2"><span class="Bold">Stop your NSAID medicine and call your healthcare provider right away if you have any of the following symptoms:</span></td></tr>
<tr>
<td align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li>more tired or weaker than usual</li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></li>
<li>your skin or eyes look yellow</li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li>flu-like symptoms</li>
<li>vomit blood</li>
</ul></td>
<td align="left"><ul class="Disc">
<li>there is blood in your bowel movement or it is black and sticky like tar</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li>unusual <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the arms and legs, hands and feet</li>
</ul></td>
</tr>
</tbody>
</table>
<p>These are not all of the possible side effects with NSAID medicines. Talk to your healthcare provider or pharmacist for more information about NSAID medicines. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">Other information about Non–Steroidal Anti–Inflammatory Drugs (NSAIDs)</span></p>
<ul class="Disc">
<li>Aspirin is an NSAID medicine but it does not increase the chance of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>. Aspirin can cause <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the brain, stomach, and intestines. Aspirin can also cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestines.</li>
<li>Some of these NSAID medicines are sold in lower doses without a prescription (over-the-counter). Talk to your healthcare provider before using over-the-counter NSAIDs for more than 10 days.</li>
</ul>
<p><span class="Bold"><span class="Underline">NSAID medicines that need a prescription</span></span></p>
<table width="75%">
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="75%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Generic Name</th>
<th class="Rrule" align="left">TRADENAME</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Vicoprofen contains the same dose of ibuprofen as over-the-counter (OTC) NSAIDs, and is usually used for less than 10 days to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. The OTC NSAID label warns that long-term continuous use may increase the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Celecoxib </td>
<td class="Rrule" align="left">Celebrex </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Diclofenac </td>
<td class="Rrule" align="left">Zorvolex, Cataflam, Cambia, Voltaren, Voltaren gel, Arthrotec (combined with misoprostol), Flector, Zipsor, Pennsaid</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Diflunisal</td>
<td class="Rrule" align="left">Dolobid</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Etodolac</td>
<td class="Rrule" align="left">Lodine, Lodine XL</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Fenoprofen</td>
<td class="Rrule" align="left">Nalfon, Nalfon 200</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Flurbiprofen </td>
<td class="Rrule" align="left">Ansaid </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ibuprofen</td>
<td class="Rrule" align="left">Motrin, Tab-Profen, Vicoprofen<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a> (combined with hydrocodone), Combunox (combined with oxycodone), DUEXIS (combined with famotidine)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Indomethacin</td>
<td class="Rrule" align="left">Tivorbex, Indocin, Indocin SR, Indo-Lemmon, Indomethagan</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ketoprofen</td>
<td class="Rrule" align="left">Oruvail, Nexcede</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ketorolac</td>
<td class="Rrule" align="left">Toradol, Sprix</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Mefenamic Acid</td>
<td class="Rrule" align="left">Ponstel</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Meloxicam</td>
<td class="Rrule" align="left">Mobic</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Nabumetone</td>
<td class="Rrule" align="left">Relafen</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Naproxen</td>
<td class="Rrule" align="left">Naprosyn, Anaprox, Anaprox DS, EC-Naprosyn, Naprelan, Naprapac (copackaged with lansoprazole), Treximet (combined with sumatriptan succinate), VIMOVO (combined with esomeprazole magnesium)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Oxaprozin</td>
<td class="Rrule" align="left">Daypro</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Piroxicam</td>
<td class="Rrule" align="left">Feldene</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Sulindac</td>
<td class="Rrule" align="left">Clinoril</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Tolmetin</td>
<td class="Rrule" align="left">Tolectin, Tolectin DS, Tolectin 600</td>
</tr>
</tbody>
</table>
<p><span class="Bold">What other important information should I know about VIMOVO?</span></p>
<p><span class="Bold">VIMOVO may help your acid-related symptoms, but you could still have serious stomach problems. Talk with your healthcare provider. </span></p>
<p><span class="Bold">VIMOVO can cause other serious side effects, including:</span></p>
<ul class="Disc">
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></span>. VIMOVO may increase your risk of getting severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. This <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> may be caused by an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> <span class="Italics">(Clostridium difficile)</span> in your intestines. Call your healthcare provider right away if you have watery stool, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> that does not go away.</li>
<li>
<span class="Bold">Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span></span>. People who take multiple daily doses of proton pump inhibitor medicines for a long period of time (a year or longer) may have an increased risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> of the hip, wrist, or spine. You should take VIMOVO exactly as prescribed, at the lowest dose possible for your treatment and for the shortest time needed. Talk to your healthcare provider about your risk of bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> if you take VIMOVO.</li>
</ul>
<p>VIMOVO can have other serious side effects. See <span class="Bold">"<a href="#mostimportant">What is the most important information I should know about VIMOVO</a>?" and "<a href="#sidefx">What are the possible side effects of VIMOVO</a>?"</span></p>
<p><span class="Bold">What is VIMOVO?</span></p>
<p>VIMOVO contains 2 medicines: naproxen, a non-steroidal anti-inflammatory drug (NSAID) and esomeprazole magnesium, a proton pump inhibitor (PPI).</p>
<p>VIMOVO is a prescription medicine used to:</p>
<ul>
<li>relieve signs and symptoms of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>, <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, and <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">ankylosing spondylitis</span></li>
<li>decrease the risk of developing stomach (gastric) <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in people who are at risk of developing <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span> with NSAIDs</li>
</ul>
<p>It is not known if VIMOVO is safe or effective in children under the age of 18.</p>
<p><span class="Bold">Who should not take VIMOVO? </span></p>
<p><span class="Bold">Do not take VIMOVO: </span></p>
<ul>
<li>If you had an <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, or other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> after taking aspirin or other NSAID medicine.</li>
<li>If you are allergic to any of the ingredients in VIMOVO. See the end of this Medication Guide for a complete list of ingredients in VIMOVO.</li>
<li>If you are allergic to any other Proton Pump Inhibitor (PPI) medicine.</li>
<li>For <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> right before or after heart bypass surgery</li>
</ul>
<p><span class="Bold">What should I tell my healthcare provider before taking VIMOVO?</span></p>
<p><span class="Bold">Before you take VIMOVO, tell your healthcare provider about all your medical conditions, including if you:</span></p>
<ul>
<li>have been told that you have low magnesium levels in your blood</li>
<li>have liver or kidney problems</li>
<li>have <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> or Crohn's disease (<span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span> or IBD)</li>
<li>have any other medical conditions</li>
<li>are pregnant or plan to become pregnant. See "<a href="#mostimportant">What is the most important information I should know about VIMOVO</a>?"</li>
<li>are breastfeeding or plan to breastfeed. VIMOVO may pass into your breast milk.  Talk to your healthcare provider about the best way to feed your baby if you take VIMOVO. </li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take,</span> including prescription and non-prescription drugs, vitamins, and herbal supplements. Since VIMOVO contains naproxen, talk to your healthcare provider before taking any other NSAID-containing products. Taking VIMOVO with other medicines can cause serious side effects. VIMOVO may affect the way other medicines work, and other medicines may affect how VIMOVO works.</p>
<p>Especially tell your healthcare provider if you take:</p>
<ul class="Disc">
<li>steroid hormones (corticosteroids)</li>
<li>St. John's Wort</li>
<li>rifampin (Rifater, Rifamate, Rimactane, Rifadin)</li>
<li>a medicine for high blood pressure or heart problems</li>
<li>aspirin</li>
<li>cholestyramine (Questran, Questran Light, Locholest, Locholest Light, Prevalite)</li>
<li>cyclosporine (Gengraf, Neoral, Sandimmune) or tacrolimus (Prograf)</li>
<li>a water pill (diuretic)</li>
<li>lithium carbonate</li>
<li>methotrexate</li>
<li>a blood thinner medicine</li>
<li>an antidepressant medicine</li>
<li>atazanavir (Reyataz)</li>
<li>ketoconazole (Nizoral)</li>
<li>products that contain iron</li>
<li>digoxin (Lanoxin)</li>
<li>erlotinib (Tarceva)</li>
<li>clopidogrel (Plavix)</li>
<li>mycophenolate mofetil (Cellcept)</li>
</ul>
<p>Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure.</p>
<p>Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take VIMOVO?</span></p>
<ul>
<li>Take VIMOVO exactly as your healthcare provider tells you to take it.</li>
<li>Your healthcare provider may tell you to take Vitamin D and Calcium supplements during treatment with VIMOVO.</li>
<li>Your healthcare provider will tell you how many VIMOVO to take and when to take them.</li>
<li>Do not change your dose or stop VIMOVO without first talking to your healthcare provider.</li>
<li>Take VIMOVO at least 30 minutes before a meal.</li>
<li>Swallow VIMOVO tablets whole with liquid. Do not split, chew, crush or dissolve the VIMOVO tablet. Tell your healthcare provider if you cannot swallow the tablet whole. You may need a different medicine.</li>
<li>You may use antacids while taking VIMOVO.</li>
<li>If you forget to take a dose of VIMOVO, take it as soon as you remember. If it is almost time for your next dose, do not take the missed dose. Take the next dose on time. Do not take 2 doses at one time to make up for a missed dose.</li>
<li>If you take too much VIMOVO, tell your healthcare provider or go to the closest hospital emergency room right away. Symptoms that you have taken too much VIMOVO may include:<table class="Noautorules" width="100%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="left"><ul class="Disc">
<li>feeling weak and tired</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li>feeling <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span></li>
<li>upper stomach-area <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span></li>
<li><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>, or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li>a change in breathing or you stop breathing</li>
</ul></td>
<td align="left" valign="middle"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></li>
<li>movements of a body part that you cannot control</li>
<li>coordination problems and decreased movement</li>
</ul></td>
</tr></tbody>
</table>
</li>
</ul>
<ul class="Disc"><li>Your healthcare provider may do certain tests from time to time to check you for side effect of VIMOVO.</li></ul>
<p><span class="Bold">What should I avoid while taking VIMOVO?</span></p>
<p>VIMOVO can cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. You should not drive or do other activities that require you to be alert until you know how VIMOVO affects you.</p>
<p><a name="sidefx"></a><span class="Bold">What are the possible side effects of VIMOVO?</span></p>
<p><span class="Bold">VIMOVO may cause serious side effects, including:  </span></p>
<ul class="Disc">
<li>See "<a href="#mostimportant">What is the most important information I should know about VIMOVO</a>?"</li>
<li><span class="Bold">High blood pressure.</span></li>
<li>
<span class="Bold">Heart problems</span> such as <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. Tell your healthcare provider about any <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your body, hands or feet, sudden <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or trouble breathing.</li>
<li>
<span class="Bold">Active <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. </span>Tell your healthcare provider if you have signs of active <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> including:<ul class="Disc">
<li>passing black sticky bowel movements (stools)</li>
<li>having <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> up blood or dark particles that look like coffee grounds</li>
</ul>
</li>
<li>
<span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>. </span>Tell your healthcare provider or get medical help right away if you develop sudden <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your lips, tongue, throat or body, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> or problems breathing or swallowing (severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>).</li>
<li>
<span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>. </span>Tell your healthcare provider or get medical help right away if you develop:<ul class="Disc">
<li>reddening of your skin with <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> or <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> </li>
<li><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> of your lips, eye lids, mouth, nose, and genitals.</li>
</ul>
</li>
<li>
<span class="Bold">Liver problems. </span>Tell your healthcare provider if you develop:<ul class="Disc">
<li>yellowing of the skin or the whites of your eyes</li>
<li>dark urine</li>
<li>feel tired</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li>right upper stomach area (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li>flu-like symptoms</li>
</ul>
</li>
<li>
<span class="Bold">Chronic (lasting a long time) <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the stomach lining (<span class="product-label-link" type="condition" conceptid="192667" conceptname="Atrophic gastritis">Atrophic Gastritis</span>). </span>Using VIMOVO for a long period of time may increase the risk of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> to your stomach lining. You may or may not have symptoms. Tell your healthcare provider if you have <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>.</li>
<li>
<span class="Bold">Vitamin B-12 deficiency.</span> VIMOVO reduces the amount of acid in your stomach.  Stomach acid is needed to absorb vitamin B-12 properly.  Talk with your doctor about the possibility of vitamin B-12 deficiency if you have been on VIMOVO for a long time (more than 3 years).</li>
<li>
<span class="Bold">Low magnesium levels in your body</span>. Low magnesium can happen in some people who take a proton pump inhibitor medicine for at least 3 months. If low magnesium levels happen, it is usually after a year of treatment.</li>
</ul>
<p>You may or may not have symptoms of low magnesium. <span class="Bold">Tell your healthcare provider right away if you have any of these symptoms:</span></p>
<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li>abnormal or fast heart beat</li>
<li><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">jitteriness</span></li>
<li>jerking movements or <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> (<span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span></li>
<li><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> of the hands and feet</li>
<li><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span> or <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span></li>
<li>spasm of the voice box</li>
</ul>
<p>Your healthcare provider may check the level of magnesium in your body before you start taking VIMOVO, during treatment, or if you will be taking VIMOVO for a long period of time.</p>
<p>The most common side effects of VIMOVO include:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the lining of the stomach, with or without loss of the protective layer of the stomach (erosive <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">stomach ulcers</span></li>
<li>upper stomach-area (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
</ul>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of VIMOVO. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store VIMOVO?</span></p>
<ul class="Disc">
<li>Store VIMOVO at room temperature between 68°F to 77°F (20°C to 25°C)</li>
<li>Keep VIMOVO in the original container and keep the bottle tightly closed.</li>
<li>Keep VIMOVO dry.</li>
</ul>
<p><span class="Bold">Keep VIMOVO and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about VIMOVO</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in this Medication Guide. Do not use VIMOVO for a condition for which it was not prescribed. Do not give VIMOVO to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about VIMOVO. If you would like more information, ask your healthcare provider. You can ask your healthcare provider or pharmacist for information that is written for healthcare professionals.</p>
<p>For more information, call 1-866-479-6742 or go to www.VIMOVO.com.</p>
<p><span class="Bold">What are the ingredients in VIMOVO?</span></p>
<p><span class="Bold">Active ingredients</span>: naproxen and esomeprazole magnesium</p>
<p><span class="Bold">Inactive ingredients:</span> carnauba wax, colloidal silicon dioxide, croscarmellose sodium, iron oxide yellow, glyceryl monostearate, hypromellose, iron oxide black, magnesium stearate, methacrylic acid copolymer dispersion, methylparaben, polysorbate 80, polydextrose, polyethylene glycol, povidone, propylene glycol, propylparaben, titanium dioxide, and triethyl citrate.</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-18"></a><p></p>
<p class="First">Distributed by:  Horizon Pharma USA, Inc., Deerfield, IL 60015</p>
<p>Revised 6/2014</p>
<p>VIMOVO is a trademark of the AstraZeneca group of companies.<br>The VIMOVO trademark has been licensed to Horizon Pharma for use in the US.<br>Other trademarks are the property of AstraZeneca respective companies.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 375 mg/20 mg Tablet Bottle Label</span></p>
<p>NDC 75987-031-04<br><span class="Bold">60 tablets</span></p>
<p><span class="Bold">VIMOVO</span><span class="Sup">®</span><br><span class="Bold">(naproxen and esomeprazole<br>magnesium)<br>delayed release tablets</span></p>
<p><span class="Bold">375 mg/20 mg*</span></p>
<p>*Each tablet contains 22.3 mg<br>esomeprazole magnesium, equivalent<br>to 20 mg of esomeprazole.</p>
<p><span class="Bold">Dispense the enclosed Medication<br>Guide to each patient.</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">HORIZON</span><br>PHARMA</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 375 mg/20 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=baa47781-7151-4c75-a9a2-d2eac0a7d55e&amp;name=vimovo-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-20"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 500 mg/20 mg Tablet Bottle Label</span></p>
<p>NDC 75987-030-04<br><span class="Bold">60 tablets</span></p>
<p><span class="Bold">VIMOVO</span><span class="Sup">®</span><br><span class="Bold">(naproxen and esomeprazole<br>magnesium)<br>delayed release tablets</span></p>
<p><span class="Bold">500 mg/20 mg*</span></p>
<p>*Each tablet contains 22.3 mg<br>esomeprazole magnesium, equivalent<br>to 20 mg of esomeprazole.</p>
<p><span class="Bold">Dispense the enclosed Medication<br>Guide to each patient.</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">HORIZON</span><br>PHARMA</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 500 mg/20 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=baa47781-7151-4c75-a9a2-d2eac0a7d55e&amp;name=vimovo-05.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VIMOVO 		
					</strong><br><span class="contentTableReg">naproxen and esomeprazole magnesium tablet, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:75987-031</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Naproxen</strong> (Naproxen) </td>
<td class="formItem">Naproxen</td>
<td class="formItem">375 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Esomeprazole Magnesium</strong> (Esomeprazole) </td>
<td class="formItem">Esomeprazole</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHACRYLIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CARNAUBA WAX</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYDEXTROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERYL MONOSTEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">17mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">375;20</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:75987-031-04</td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022511</td>
<td class="formItem">01/01/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VIMOVO 		
					</strong><br><span class="contentTableReg">naproxen and esomeprazole magnesium tablet, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:75987-030</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Naproxen</strong> (Naproxen) </td>
<td class="formItem">Naproxen</td>
<td class="formItem">500 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Esomeprazole Magnesium</strong> (Esomeprazole) </td>
<td class="formItem">Esomeprazole</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHACRYLIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CARNAUBA WAX</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYDEXTROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERYL MONOSTEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">500;20</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:75987-030-04</td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:75987-030-73</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">6  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022511</td>
<td class="formItem">01/01/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Horizon Pharma Inc.
							(964613413)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Patheon Pharmaceuticals Inc.</td>
<td class="formItem"></td>
<td class="formItem">005286822</td>
<td class="formItem">MANUFACTURE(75987-030, 75987-031)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Divi's Laboratories Limited [Unit-1]</td>
<td class="formItem"></td>
<td class="formItem">918598199</td>
<td class="formItem">API MANUFACTURE(75987-030, 75987-031)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">MINAKEM Dunkerque</td>
<td class="formItem"></td>
<td class="formItem">277412599</td>
<td class="formItem">API MANUFACTURE(75987-030, 75987-031)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">AstraZeneca Pharmaceuticals LP</td>
<td class="formItem"></td>
<td class="formItem">054743190</td>
<td class="formItem">PACK(75987-030, 75987-031), LABEL(75987-030, 75987-031)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Divi's Laboraties Limited [Unit-2]</td>
<td class="formItem"></td>
<td class="formItem">676446492</td>
<td class="formItem">API MANUFACTURE(75987-030, 75987-031)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>027b1651-cb63-42e2-8c15-e7bb930f20ce</div>
<div>Set id: baa47781-7151-4c75-a9a2-d2eac0a7d55e</div>
<div>Version: 5</div>
<div>Effective Time: 20150625</div>
</div>
</div> <div class="DistributorName">Horizon Pharma Inc.</div></p>
</body></html>
